<SEC-DOCUMENT>0001104659-25-061182.txt : 20250620
<SEC-HEADER>0001104659-25-061182.hdr.sgml : 20250620
<ACCEPTANCE-DATETIME>20250620162811
ACCESSION NUMBER:		0001104659-25-061182
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250620
DATE AS OF CHANGE:		20250620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279077
		FILM NUMBER:		251061789

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2518361d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="background-color: white"><B>Filed
Pursuant to Rule&nbsp;424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="background-color: white"><B>Registration
Statement No.&nbsp;333-279077</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Prospectus Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>(To Prospectus dated September&nbsp;25,
2024)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2518361d1_424b5img001.jpg" ALT="" STYLE="height: 0.45in; width: 1.52in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $2,534,352 of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We have
entered into an Amended and Restated At Market Issuance Sales Agreement, dated February&nbsp;9, 2021, as amended by Amendment No.&nbsp;1
thereto, dated May&nbsp;3, 2021, as further amended by Amendment No.&nbsp;2 thereto, dated May&nbsp;2, 2024 (the &ldquo;Sales Agreement&rdquo;),
with A.G.P./Alliance Global Partners (&ldquo;AGP&rdquo; or the &ldquo;Sales Agent&rdquo;), relating to the sale of shares of our common
stock, par value $0.001 per share (the &ldquo;common stock&rdquo;), offered by this prospectus supplement and the accompanying base prospectus.
During the year ended December&nbsp;31, 2024 through the date hereof, we sold through the Sales Agreement approximately 569,000 shares
of our common stock and received net proceeds of approximately $3.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On June&nbsp;17,
2025, the last reported sale price of our common stock on the NYSE American LLC was $0.465 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our common stock, if any, under this
prospectus supplement will be made by any method permitted that is deemed an &ldquo;at the market offering&rdquo; as defined in Rule&nbsp;415
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The Sales Agent is not required to sell any specific
amount but will act as our Sales Agent using commercially reasonable efforts consistent with its normal trading and sales practices, on
mutually agreed terms between the Sales Agent and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent will be entitled to compensation
at a commission rate equal to up to 3.0% of the gross sales price per share sold. In connection with the sale of the common stock on our
behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act and the compensation
of the Sales Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution
to the Sales Agent with respect to certain liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates is approximately $12,940,401.76, which is calculated based on 9,049,241
shares of our outstanding common stock held by non-affiliates and a price of $1.43 per share, the closing price of our common stock on
April&nbsp;23, 2025, which is the highest closing sale price of our common stock on the NYSE American LLC within the prior 60 days of
this prospectus. During the prior twelve calendar month period that ends on and includes the date hereof, we have offered and sold approximately
$1,779,115 of shares of our common stock pursuant to General Instruction I.B.6 to Form&nbsp;S-3. As a result, pursuant to General Instruction
I.B.6 to Form&nbsp;S-3 and in accordance with the terms of the Sales Agreement, we may offer and sell through <FONT STYLE="background-color: white">this
prospectus supplement and the accompanying base prospectus</FONT> additional shares of our common stock having an aggregate offering price
of up to $2,534,352 from time to time through or to the Sales Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our public float increases such that we may
sell additional amounts under the Sales Agreement and the registration statement of which this prospectus supplement is a part, we will
file a prospectus supplement prior to making additional sales. In no event will we sell securities in public primary offerings on Form&nbsp;S-3
with a value exceeding more than one-third of our public float (as defined by General Instruction I.B.6 to Form&nbsp;S-3) in any 12 calendar
month period so long as our public float remains below $75 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves a high
degree of risk. Before making an investment decision, please read the information under the heading &ldquo;Risk Factors&rdquo; beginning
on page&nbsp;S-5 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement, and the
accompanying base prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus
supplement or the accompanying base prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is&nbsp;June&nbsp;20,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: White">
    <TD STYLE="padding: 0.25pt 0.25pt 1pt; vertical-align: top; width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center">&nbsp;</TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#ATPS_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#ATPS_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-i<U>i</U></FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#IAMDS_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDUSTRY
    AND MARKET DATA</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#IAMDS_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-iv</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#PSSS_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#PSSS_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#TOS_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#TOS_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#RFS_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#RFS_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<U>5</U></FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#SNRFLSS_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#SNRFLSS_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#UOPS_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF
    PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#UOPS_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#DPS_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
    POLICY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#DPS_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-<U>10</U></FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#DS_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#DS_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#PODS_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF
    DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#PODS_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#LMS_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
    MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#LMS_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#ES_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#ES_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#WYCFMIS_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#WYCFMIS_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></A></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0.25pt"><A HREF="#IOCDBRS_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: center"><A HREF="#IOCDBRS_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></A></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#ATP_015"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ABOUT THIS Prospectus </FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#ATP_015">ii</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#PS_016"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#PS_016">1</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#RF_017"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#RF_017">6</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#FLS_018"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#FLS_018">7</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#UOP_019"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#UOP_019">8</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#DOCS_020"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOCS_020">9</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#DODS_021"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description of Debt Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DODS_021">14</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#DOW_022"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description of Warrants</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOW_022">20</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#DOU_023"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description of Units</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOU_023">22</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#LOS_024"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Legal Ownership of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#LOS_024">23</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#POD_025"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#POD_025">26</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#LM_026"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#LM_026">28</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#E_027"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#E_027">28</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#WTCFMI_028"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#WTCFMI_028">28</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#IOCBR_029"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#IOCBR_029">28</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ATPS_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
base prospectus are part of a &ldquo;shelf&rdquo; registration statement on Form&nbsp;S-3 (File No.&nbsp;333-279077) that we filed with
the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on May&nbsp;2, 2024, as amended by Amendment No.&nbsp;1 thereto filed
with the SEC on September&nbsp;11, 2024 and was declared effective on September&nbsp;25, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement describes the specific
terms of this offering and also adds to and updates information contained in the accompanying base prospectus and the documents incorporated
by reference into this prospectus supplement and the accompanying base prospectus. The accompanying base prospectus, including the documents
incorporated by reference, provides more general information. To the extent there is a conflict between the information contained in this
prospectus supplement, on the one hand, and the information contained in the accompanying base prospectus or in any document incorporated
by reference that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information
in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having
a later date &mdash; for example, a document incorporated by reference in the accompanying base prospectus &mdash; the statement in the
document having the later date modifies or supersedes the earlier statement. You should read this prospectus supplement and the accompanying
base prospectus, including the information incorporated by reference and any free writing prospectus that we have authorized for use in
connection with this offering, in their entirety before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
or incorporated by reference in this prospectus supplement and the accompanying base prospectus, along with the information contained
in any free writing prospectus that we have authorized for use in connection with this offering. We have not authorized anyone to provide
you with different or additional information. You should assume that the information appearing in this prospectus supplement, the accompanying
base prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus, and in any
free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the respective dates of
those documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus
supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made; therefore, such
representations, warranties and covenants should not be relied on as accurate representations of the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we have indicated otherwise, or the context
otherwise requires, references in this prospectus supplement and the accompanying base prospectus to &ldquo;Theriva,&rdquo; the &ldquo;Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Theriva Biologics,&nbsp;Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement, the accompanying base
prospectus and the information incorporated by reference includes trademarks, service marks and trade names owned by us or other companies.
All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying
base prospectus are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">We are offering
to sell, and are seeking offers to buy, the common stock only in jurisdictions where such offers and sales are permitted. No action has
been or will be taken in any jurisdiction by us or the Sales Agent that would permit a public offering of the common stock or the possession
or distribution of this prospectus supplement and the accompanying base prospectus in any jurisdiction, other than in the United States.
Persons outside the United States who come into possession of this prospectus supplement and the accompanying base prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement
and the accompanying base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by
this prospectus supplement and the accompanying base prospectus by any person in any jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus is part of a registration statement that we have filed with the SEC utilizing a &ldquo;shelf&rdquo; registration process. Under
the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $200,000,000 under
the accompanying base prospectus. Under this prospectus supplement and the accompanying base prospectus, we may offer shares of our common
stock having an aggregate offering price of up to $2,534,352 from time to time at prices and on terms to be determined by market conditions
at the time of offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We provide information to you about this offering
of shares of our common stock in two separate documents that are bound together: (1)&nbsp;this prospectus supplement, which describes
the specific details regarding this offering; and (2)&nbsp;the accompanying base prospectus, which provides general information, some
of which may not apply to this offering. Generally, when we refer to this &ldquo;prospectus,&rdquo; we are referring to both documents
combined. If information in this prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this
prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having
a later date&mdash;for example, a document incorporated by reference in this prospectus supplement&mdash;the statement in the document
having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects
may have changed since the earlier dates. This prospectus supplement, the accompanying base prospectus and the documents incorporated
into each by reference include important information about us, the securities being offered and other information you should know before
investing in our securities. You should also read and consider information in the documents we have referred you to in the section of
this prospectus supplement and the accompanying base prospectus entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on this prospectus supplement,
the accompanying base prospectus and the information incorporated or deemed to be incorporated by reference therein. We have not and the
Sales Agent has not authorized anyone to provide you with information that is in addition to or different from that contained or incorporated
by reference in this prospectus supplement and the accompanying base prospectus. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not offering to sell these securities in any jurisdiction where the offer or sale is not
permitted. You should not assume that the information contained or incorporated by reference in this prospectus supplement or the accompanying
base prospectus is accurate as of any date other than as of the date of this prospectus supplement or the accompanying base prospectus,
as the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery
of this prospectus supplement and the accompanying base prospectus or any sale of our securities. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying
base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating
risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such
representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action has been or will be taken in any jurisdiction
by us or the Sales Agent that would permit a public offering of the common stock or the possession or distribution of this prospectus
supplement and the accompanying base prospectus in any jurisdiction, other than in the United States. Persons outside the United States
who come into possession of this prospectus supplement and the accompanying base prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying
base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not constitute, and may
not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement
and the accompanying base prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or
solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="IAMDS_002"></A><B>INDUSTRY AND MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We obtained the industry and market data in this
prospectus supplement from our own research as well as from industry and general publications, surveys and studies conducted by third
parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate
is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus supplement and in the documents incorporated by reference in this prospectus supplement.
These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="PSSS_003"></A><B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information contained
elsewhere in this prospectus supplement, the accompanying prospectus or incorporated by reference in this prospectus supplement. This
summary does not contain all the information you should consider before investing in our common stock. You should read the following summary
together with the more detailed information appearing in this prospectus supplement, the accompanying prospectus and the information incorporated
by reference in their entirety, including our consolidated financial statements and related notes as well as the section entitled &ldquo;Risk
Factors&rdquo; herein and in the documents incorporated by reference, before making any investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a diversified clinical-stage company developing
therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the acquisition in March&nbsp;2022
of Theriva Biologics, S.L. (&ldquo;VCN&rdquo;, formerly named VCN Biosciences, S.L.), described in more detail below (the &ldquo;Acquisition&rdquo;),
we transitioned our strategic focus to oncology through the development of VCN&rsquo;s new oncolytic adenovirus platform designed for
intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor,
and to promote a robust and sustained anti-tumor response by the patient&rsquo;s immune system. Our lead product candidate, VCN-01, a
clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express an enzyme, PH20 hyaluronidase,
is currently being evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer (&ldquo;VIRAGE&rdquo;), and has recently
been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma, and Phase 1 clinical studies for the treatment
of other solid tumors including head and neck squamous cell carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition, our focus was on developing
therapeutics designed to treat gastrointestinal (GI) diseases which included our clinical development candidates: (1)&nbsp;SYN-004 (ribaxamase)
which is designed to degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within the GI tract to prevent microbiome
damage, thereby preventing overgrowth and infection by pathogenic organisms such as&nbsp;<I>Clostridioides difficile</I>&nbsp;infection
(CDI) and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in
allogeneic hematopoietic cell transplant (HCT) recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme intestinal
alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. As part of our strategic
transformation into an oncology focused company, we are exploring value creation options for our SYN-004 and SYN-020 assets, including
out-licensing or partnering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financial Developments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;8, 2025, we consummated a public offering
(the &ldquo;May&nbsp;2025 Offering&rdquo;) of an aggregate of (i)&nbsp;1,990,900 sharesof our common stock, (ii)&nbsp;pre-funded warrants
(&ldquo;Pre-Funded Warrants&rdquo;) to purchase up to 4,827,280 shares of common stock (the &ldquo;Pre-Funded Warrant Shares&rdquo;),
and (iii)&nbsp;common stock purchase warrants (&ldquo;Common Warrants&rdquo;) to purchase up to 6,818,180 shares of common stock (the
 &ldquo;Common Warrant Shares&rdquo;). Each share of common stock and associated Common Warrant to purchase one (1)&nbsp;Common Warrant
Share was sold at a combined public offering price of $1.10. Each Pre-Funded Warrant and associated Common Warrant to purchase one (1)&nbsp;Common
Warrant Share was sold at a combined public offering price of $1.099. We received aggregate gross proceeds from the May&nbsp;2025 Offering
of approximately $7.5 million, before deducting placement agent fees and other offering expenses. We intend to use the proceeds of the
May&nbsp;2025 Offering primarily for working capital and general corporate purposes, including for research and development and manufacturing
scale-up and may use a portion of the proceeds to invest in or acquire other products, businesses or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;3, 2025, we received $1.7 million
for the 2023 Research and Development rebate program sponsored by the Spanish government. The program provides for reimbursement of certain
expenses incurred in research and development efforts we incur in Spain. The reimbursements can be through either tax credits or direct
refunds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;16, 2024, we issued a
press release noting that our THERICEL project had been awarded &euro;2.28 million (approximately $2.54 million) from the National
Knowledge Transfer Program of the Spanish government&rsquo;s Ministry of Science,&nbsp;Innovation&nbsp;&amp; Universities to support
a collaboration between us and the Universitat Aut&ograve;noma de Barcelona (&ldquo;UAB&rdquo;) to advance the our suspension cell
platform for the clinical manufacture of adenovirus- and adeno-associated virus (&ldquo;AAV&rdquo;) therapies. Under the award, we
(via our wholly owned subsidiary, Theriva Biologics SL) will receive an unsecured loan (the &ldquo;Loan&rdquo;) of &euro;1.3 million
(approximately $1.4 million) as a lump sum payment in Q1 2025 which shall bear interest at a rate of 4.015% and be repaid over 7
years commencing three years from the date of award and UAB will receive a grant of &euro;0.95 million (approximately $1.06 million)
dedicated to the THERICEL project and paid in annual installments over the next 3 years. The loan was funded on January&nbsp;17,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Current Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2518361d1_424b5img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>*Based on management&rsquo;s current beliefs and expectations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>aGVHD</B>&nbsp;acute graft-versus host disease.<B>&nbsp;allo-HCT&nbsp;</B>allogeneic
hematopoietic cell transplant.&nbsp;<B>CSR</B>&nbsp;clinical study report.&nbsp;<B>HNSCC</B>&nbsp;head and neck squamous cell carcinoma.&nbsp;<B>IV</B>&nbsp;intravenous.&nbsp;<B>IVit</B>&nbsp;intravitreal.
For other abbreviations see the text.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&sup1;Additional products with preclinical proof-of-concept include
SYN-006 (carbapenemase) to prevent aGVHD, CDI, and microbiome damage in patients treated with carbapenem antibiotics and SYN-007 (ribaxamase)
DR to prevent antibiotic associated diarrhea with oral &beta;-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&sup2;Depending on funding/partnership. SYN-004 may enter a U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;)-agreed Phase 3 clinical trial for the treatment of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B><I>Recent Clinical Developments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;7, 2025, we announced positive topline
outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company&rsquo;s lead product candidate VCN-01 (zabilugene almadenorepvec)
plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal
adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option. VCN-01 is a systemically-administered,
tumor selective, stroma-degrading oncolytic adenovirus that has been granted Orphan Drug Designation and Fast Track Designation by the
U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The analysis of the VIRAGE trial (see &ldquo;About
VIRAGE&rdquo; below) includes data for first-line treatment of 96 newly-diagnosed metastatic PDAC patients:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the primary endpoint analysis, the 48 patients
treated with at least one dose of gemcitabine/nab-paclitaxel SoC had a median overall survival (OS) of 8.6 months, while the 48 patients
treated with VCN-01 followed by at least one dose of gemcitabine/nab-paclitaxel SoC had a median OS of 10.8 months [Hazard Ratio (HR)
= 0.57, 95% CI 0.34-0.96, p=0.0546].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The improvements in OS in the VCN-01+SoC treatment
arm compared to the SoC control arm were reflected in increased progression free survival (PFS) [median PFS 7.0 vs 4.6 months; HR = 0.55,
95% CI 0.34-0.88, p= 0.0105].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The median duration of response (DoR) was 5.4
months (n=15) in the SoC control arm, while the median DoR in the VCN-01+SoC treatment arm was doubled to 11.2 months (n=19, HR = 0.22,
95% CI 0.08-0.62, p=0.0035).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The increase in OS was greater for patients who
received 2 doses of VCN-01 and 4 or more cycles of gemcitabine/nab-paclitaxel SoC (n=34) compared with patients who received 4 or more
cycles of gemcitabine/nab-paclitaxel SoC (n=29) [median OS 14.8 and 11.6 months respectively; HR=0.44, 95% CI: 0.21-0.92, p=0.046], suggesting
that the second dose of VCN-01 (administered 3 months after the first dose) provides a meaningful additional benefit in this treatment
subgroup.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;31, 2025, we announced that a second
Independent Data Monitoring Committee (IDMC) review of data from the VIRAGE Phase 2b clinical trial in newly-diagnosed metastatic pancreatic
ductal adenocarcinoma (PDAC) found that VCN-01 was well tolerated in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel)
and the adverse event (AE) profile was as expected for the patient population and the medications being studied. The VCN-01 AE profile
was consistent with that observed in prior clinical trials. The most common VCN-01 related AEs (pyrexia, flu-like illness, vomiting, nausea,
and elevated transaminases) were transient and reversible. These AEs were observed to be less frequent and of reduced CTCAE grade after
the second VCN-01 dose (administered on day 92) compared to the first VCN-01 dose (administered on day 1). The IDMC noted that the overall
type and number of AEs in the VCN-01 treatment group was as expected for the pancreatic cancer population, the duration of treatment,
and the administration of an oncolytic virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">Our predecessor,
Sheffield Pharmaceuticals,&nbsp;Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics,&nbsp;Inc.,
a publicly-traded Delaware corporation formed in 2001. After the reverse merger, we changed our name to Pipex Pharmaceuticals,&nbsp;Inc.,
and in October&nbsp;2008 we changed our name to Adeona Pharmaceuticals,&nbsp;Inc. On October&nbsp;15, 2009, we engaged in a merger with
a wholly owned subsidiary for the purpose of reincorporating in the State of Nevada. On February&nbsp;15, 2012, we changed our name to
Synthetic Biologics,&nbsp;Inc. On August&nbsp;10, 2018, we effected a one for thirty-five reverse stock split of our authorized, issued
and outstanding common stock. On July&nbsp;15, 2022, we effected a one for ten reverse stock split of our authorized, issued and outstanding
common stock. On October&nbsp;12, 2022, we changed our name to Theriva Biologics,&nbsp;Inc. On August&nbsp;26, 2024, we effected a one
for twenty-five reverse stock split of our authorized, issued and outstanding common stock (the &ldquo;Reverse Stock Split&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: #212529">Our
principal executive offices are located at 9605 Medical Center Drive, Suite&nbsp;270, Rockville, Maryland 20850, and our telephone number
is (301) 417-4367. Our website address is&nbsp;<I>www.therivabio.com</I>.&nbsp;Information contained on our website is intended for informational
purposes only and is not incorporated by reference into this prospectus, and it should not be considered to be part of this prospectus
or the&nbsp;registration statement of which this prospectus forms a part. The SEC maintains an internet site that contains reports, proxy
and information statements, and other information regarding issuers like us that file documents electronically with the SEC. The address
of the SEC </FONT>website is&nbsp;<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><B>Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">We are a &ldquo;smaller reporting
company&rdquo; as defined in the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). As a result, we may take
advantage of certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance
with the auditor attestation requirements pursuant to the Sarbanes-Oxley Act of 2022, reduced disclosure about our executive compensation
arrangements and the requirements to provide only two years of audited financial statements in our annual reports and registration statements.
We will continue to be a &ldquo;smaller reporting company&rdquo; as long as (1)&nbsp;we have a public float (i.e., the market value of
our common stock held by non-affiliates) less than $250 million calculated as of the last business day of our most recently completed
second fiscal quarter, or (2)&nbsp;our annual revenues are less than $100 million for our previous fiscal year and we have either no public
float or a public float of less than $700 million as of the end of that fiscal year&rsquo;s second fiscal quarter. Decreased disclosures
in our SEC filings due to our status as a &ldquo;smaller reporting company&rdquo; may make it harder for investors to analyze our results
of operations and financial prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="TOS_004"></A><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>All share information presented herein reflects
a 1-for-25 reverse stock split of our common stock, which we effected on&nbsp;August&nbsp;26, 2024.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 48%; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock offered by us pursuant to this prospectus supplement</B></FONT></TD>
<TD STYLE="vertical-align: bottom; width: 4%; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="padding: 0.25pt 1.05pt 0.25pt 0.25pt; vertical-align: top; width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $2,534,352.</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: top; padding: 0.25pt 1.05pt 0.25pt 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock to be outstanding after this offering<SUP>(1)</SUP></B></FONT></TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="padding: 0.25pt 1.05pt 0.25pt 0.25pt; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 14,509,451 shares, assuming sales of 5,450,219 shares of our common stock in this offering at an offering price of $0.465 per share, which was the last reported sale price of our common stock on the NYSE American on June&nbsp;17, 2025. The actual number of shares issued will vary depending on the sales price under this offering.</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1.05pt 0.25pt 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manner of offering</B></FONT></TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="padding: 0.25pt; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At the market offering&rdquo; that may be made from time to time on the NYSE American or other market for our common stock in the United States through or to the&nbsp;&nbsp;Sales Agent. See the section entitled &ldquo;Plan of Distribution&rdquo; on page&nbsp;S-12 of this prospectus supplement for additional information.</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom; padding: 0.25pt 1.05pt 0.25pt 0.25pt">We currently intend to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up. We may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although we have no commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus. See &ldquo;Use of Proceeds&rdquo; on page&nbsp;S-9 of this prospectus supplement for additional information.</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1.05pt 0.25pt 0.25pt">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="padding: 0.25pt 1.05pt 0.25pt 0.25pt; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement for a discussion of factors to consider before deciding to purchase shares of our common stock.</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1.05pt 0.25pt 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 1.05pt; padding-bottom: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE American symbol</B></FONT></TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt 1pt 0.25pt 0.25pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the NYSE American under the symbol &ldquo;TOVX&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Based on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,059,241 <FONT STYLE="background-color: white">shares of our common stock outstanding as of June&nbsp;17, 2025 and excludes:</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,126,430
shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $5.18 per
share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD STYLE="text-align: justify">8,786,686 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $1.18 per share; and &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD>1,381,136 additional shares of the common stock reserved for future issuance under our equity incentive plans. &nbsp; &nbsp; &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RFS_005"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves a high
degree of risk. This prospectus supplement does not describe all of those risks. You should consider the risk factors described in this
prospectus supplement under the caption &ldquo;Risks Related to This Offering and Our Securities&rdquo; below, as well as the those described
under the caption &ldquo;Risk Factors&rdquo; in the documents incorporated by reference herein, including our most recent Annual Report
on Form&nbsp;10-K, any subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K, and all other information contained
or incorporated by reference into this prospectus supplement and the accompanying base prospectus before deciding whether to purchase
any of the common stock being offered under this prospectus supplement. Each of the risks described below could adversely affect our business,
operating results and financial condition, as well as adversely affect the value of an investment in our common stock, and the occurrence
of any of these risks might cause you to lose all or part of your investment. Moreover, the risks described below are not the only ones
that we face. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our
business operations. Please also read carefully the section below titled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management team may invest or spend
the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion over
the use of proceeds from this offering. The net proceeds from this offering will be used primarily for general corporate purposes, which
may include, among other things, for clinical trials for our product candidates, paying general and administrative expenses and accounts
payable, increasing our working capital, funding research and development and funding capital expenditures. We may also use a portion
of the net proceeds for licensing or acquiring intellectual property to incorporate into our products and product candidates or our research
and development programs and to in-license, acquire or invest in other businesses or products, although we have no commitments or agreements
with respect to any such licenses, acquisitions or investments as of the date of this prospectus supplement. Our management will have
considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision,
to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not increase
our operating results or enhance the value of our common stock. The failure of our management to use these funds effectively could have
a material adverse effect on our business, cause the market price of our common stock to decline and impair the commercialization of our
products and/or delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering
in short-term, investment-grade, interest-bearing instruments and U.S. government securities. These investments may not yield a favorable
return to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If you purchase shares of our common stock
sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In addition,
we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The price per share of our common stock being
offered may be higher than the net tangible book value per share of our outstanding common stock prior to this offering. Assuming that
an aggregate of 5,450,219 shares of our common stock are sold at a price of $0.465 per share, the last reported sale price of our common
stock on the NYSE American on June&nbsp;17, 2025, new investors in this offering will incur immediate dilution of $0.025 per share. For
a more detailed discussion of the foregoing, see the section entitled &ldquo;Dilution&rdquo; below. To the extent outstanding stock options
or warrants are exercised, there will be further dilution to new investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution as a
result of future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise additional capital, we may in
the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices
that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price
per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities
in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common
stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share
paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not intend to declare cash
dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock
for any return on their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid cash dividends
on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business
and do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. In addition, the terms of
any future preferred stock or debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of
the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Resales of our common stock in the public
market during this offering by our stockholders may cause the market price of our common stock to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue common stock from time to time in
connection with this offering. This issuance from time to time of these new shares of our common stock, or our ability to issue these
shares of common stock in this offering, could result in resales of our</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">common stock by our current stockholders concerned
about the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The shares of common stock offered under
this prospectus supplement and the accompanying base prospectus may be sold in &ldquo;at the market offerings&rdquo;, and investors who
buy shares at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors who purchase shares under this prospectus
supplement and the accompanying base prospectus at different times will likely pay different prices, and so may experience different outcomes
in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold,
and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares as a result of share sales
made at prices lower than the prices they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The actual number of shares we will issue
under the Sales Agreement at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the sales agreement
and compliance with applicable law, we have the discretion to deliver placement notices to the Sales Agent at any time throughout the
term of the sales agreement. The number of shares that are sold by the Sales Agent as our Sales Agent after we deliver a placement notice
will fluctuate based on the market price of the common stock and the trading volume of our common stock during the sales period and limits
we set with the Sales Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B><I>The market price of
our common stock has been and may continue to be volatile and adversely affected by various factors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">Our stock
price has fluctuated in the past, has recently been volatile and may be volatile in the future. By way of example, on June&nbsp;17, 2025,
the price of our common stock closed at $0.465 per share while on June&nbsp;17, 2024, our stock price closed at $6.1875 per share with
no discernable announcements or developments by us or third parties. We may incur rapid and substantial decreases in our stock price in
the foreseeable future that are unrelated to our operating performance or prospects. In addition, the outbreak of the novel strain of
coronavirus (COVID-19) has caused broad stock market and industry fluctuations. The stock market in general and the market for biotechnology
and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance
of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The
market price of our common stock could fluctuate significantly in response to various factors and events, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">investor reaction to our business strategy;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the success of competitive products or technologies;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our continued compliance with the listing standards
of the NYSE American;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory or legal developments in the United
States and other countries, especially changes in laws or regulations applicable to our products;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">results of our clinical trials;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">actions taken by regulatory agencies with respect
to our products, clinical studies, manufacturing process or sales and marketing terms;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">variations in our financial results or those
of companies that are perceived to be similar to us;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the success of our efforts to acquire or in-license
additional products or product candidates;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developments concerning our collaborations or
partners;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developments or disputes concerning patents or
other proprietary rights, litigation matters and our ability to obtain patent protection for our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability or inability to raise additional
capital and the terms on which we raise it;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">declines in the market prices of stocks generally;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">trading volume of our common stock;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sales of our common stock by us or our stockholders;</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">general economic, industry and market conditions;
and</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212529"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">other events or factors, including those resulting
from such events, or the prospect of such events, including war, terrorism and other international conflicts, such as the conflict in
the Middle East, the conflict between Russia and the Ukraine, public health issues including health epidemics or pandemics, such as the
outbreak of the novel coronavirus (COVID-19), and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather
and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our
suppliers or result in political or economic instability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">These
broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Further,
recent increases are significantly inconsistent with any improvements in actual or expected operating performance, financial condition
or other indicators of value. Since the stock price of our common stock has fluctuated in the past, has been recently volatile and may
be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility
in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against
us, could result in substantial costs and diversion of management&rsquo;s attention and resources, which could materially and adversely
affect our business, financial condition, results of operations and growth prospects.&nbsp;There can be no guarantee that our stock price
will remain at current prices or that future sales of our common stock will not be at prices lower than those sold to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">Additionally,
recently, securities of certain companies have experienced significant and extreme&nbsp;volatility in stock price due to short sellers
of shares of common stock, known as a &ldquo;short squeeze.&rdquo; These short squeezes have caused extreme volatility in those companies
and in the market and have led the price per share of those companies to trade at a significantly inflated rate that is disconnected from
the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of
losing a significant portion of their original investment as the price per share has declined steadily as interest in those stocks have
abated. While we have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that we won&rsquo;t
be in the future, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that is significantly
disconnected from our underlying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="SNRFLSS_006"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
base prospectus and the documents we file with the SEC that are incorporated by reference herein and therein contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of
1934, as amended (the &ldquo;Exchange Act&rdquo;), these statements reflect our current views with respect to our ongoing and planned
clinical trials, business strategy, business plan, financial performance and other future events. These statements include forward-looking
statements both with respect to us, specifically, and the biotechnology sector, in general. We make these statements pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include the words &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;will&rdquo; and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the
federal securities laws or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements involve inherent
risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated
in these statements. We believe that these factors include, but are not limited to, those factors set forth under the caption &ldquo;Risk
Factors&rdquo; in this prospectus supplement and in the accompanying base prospectus and under the captions &ldquo;Risk Factors,&rdquo;
 &ldquo;Business,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
in our most recent Annual Report on Form&nbsp;10-K and our subsequent Quarterly Reports on Form&nbsp;10-Q, all of which you should review
carefully. Please consider our forward-looking statements in light of those risks as you read this prospectus supplement and the accompanying
base prospectus. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not assume that the information contained
in this prospectus supplement is accurate as of any date other than the date on the front of this prospectus supplement, or that any information
incorporated by reference into this prospectus supplement is accurate as of any date other than the date of the document so incorporated
by reference. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes
available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed
or implied in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If one or more of these or other risks or uncertainties
materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. All
subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified
in their entirety by this Note. Before purchasing any shares of common stock, you should consider carefully all of the factors set forth
or referred to in this prospectus supplement and in the accompanying base prospectus that could cause actual results to differ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="UOPS_007"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue and sell shares of our common stock
having aggregate gross proceeds of up to $2,534,352 from time to time under this prospectus supplement and the documents incorporated
by reference herein and therein. Because there is no minimum offering amount required as a condition to close this offering, the actual
total offering amount, commissions and proceeds to us, if any, are not determinable at this time. The amount of proceeds from this offering
will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance
that we will be able to sell any shares of our common stock under or fully utilize the Sales Agreement with A.G.P. as a source of financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds, if any, from
the sales of shares of our common stock offered by this prospectus supplement for working capital and general corporate purposes, including,
to acquire, license or invest in assets, businesses, technologies, product candidates or other intellectual property, to make milestone
payments and to repurchase securities. We have broad discretion in determining how the proceeds of this offering will be used, and our
discretion is not limited by the aforementioned possible uses. Our Board of Directors believes the flexibility in application of the net
proceeds is prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus supplement,
we cannot specify with certainty all of the particular uses for the net proceeds to be received from this offering. The amounts and timing
of our actual expenditures will depend on numerous factors including our operating costs and the amount of funding, if any, received from
grants. Accordingly, our management will have broad discretion in the application of the net proceeds, and investors will be relying on
the judgment of management regarding the application of the net proceeds from the offering. We may find it necessary or advisable to reallocate
the net proceeds of this offering; however, any such reallocation would be substantially limited to the categories set forth above as
we do not intend to use the net proceeds for other purposes. Pending such uses set forth above, we plan to invest the net proceeds in
government securities and other short-term investment grade, marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DPS_008"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We expect
to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination
to pay dividends, if any, on our common stock will be at the discretion of our board of directors and will depend on, among other factors,
the terms of any outstanding preferred stock, our results of operations, financial condition, capital requirements and contractual restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DS_009"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our common stock, your interest
will be diluted immediately to the extent of the difference between the offering price and the adjusted net tangible book value per share
of our common stock after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value as of March&nbsp;31,
2025 was approximately $(2.6)&nbsp;million, or $(0.93) per share, <FONT STYLE="background-color: white">based on 2,782,449 shares of our
common stock outstanding as of March&nbsp;31, 2025</FONT>. &ldquo;Net tangible book value per share&rdquo; is determined by dividing our
total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of March&nbsp;31, 2025. Dilution
with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares
of common stock in this offering and the net tangible book value per share of our Common Stock immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pro forma net tangible book value as of March&nbsp;31,
2025 was $4.0&nbsp;million or approximately $0.446 per share. Pro forma net tangible book value per shares represents our total tangible
assets as adjusted to take into account net cash proceeds of approximately $6.6 million from the issuance of the following securities:
(i)&nbsp;1,990,900&nbsp;shares of our common stock, (ii)&nbsp;pre-funded warrants to purchase up to 4,827,280&nbsp;shares of common stock,
and (iii)&nbsp;common stock purchase warrants to purchase up to 6,818,180&nbsp;shares of common stock in the May&nbsp;2025 Offering, and
our subsequent issuance of 4,287,374 shares of common stock upon the exercise of pre-funded warrants to purchase 4,287,374 shares of common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to the (i)&nbsp;pro forma
adjustments set forth above and (ii)&nbsp;the assumed sale of 5,450,219 shares of our common stock in this offering at an assumed public
offering price of $0.465 per share, which represents the closing price of our common stock on the NYSE American on June&nbsp;17, 2025
and after deducting placement agent fees and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value
as of March&nbsp;31, 2025 would have been approximately $6.4 million, or approximately $0.44 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This represents an immediate increase in net tangible
book value of $0.006 per share to existing stockholders and immediate dilution of $0.025 in net tangible book value per share to new investors
purchasing shares of common stock in this offering compared to the assumed public offering price per share in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates the per share
dilution to investors purchasing shares in an offering using this prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif">Assumed public offering price per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.465</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in">Pro forma net tangible book value per share as of March&nbsp;31, 2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.446</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Increase in pro forma net tangible book value per share attributable to new investors purchasing our common stock in this offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.006</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pro forma as adjusted net tangible book value per share after giving effect to this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.44</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dilution per share to investors purchasing our common stock in this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Based on 2,782,449 shares of our common stock outstanding as of March&nbsp;31, 2025 and excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,034 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $36.88 per share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD STYLE="text-align: justify">1,428,600 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $2.00 per share; and &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
<TD>2,332,636 additional shares of the common stock reserved for future issuance under our equity incentive plans. &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above illustration of dilution per share to
investors participating in this offering assumes no exercise of outstanding options to purchase our common stock or outstanding warrants
to purchase shares of our common stock. To the extent that any of these outstanding options or warrants are exercised or we issue additional
shares under our equity incentive plans, there will be further dilution to new investors. In addition, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="PODS_010"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This prospectus
supplement relates to the offer and sale of up to $2,534,352 shares of our common stock pursuant to the Sales Agreement. The sales of
shares of our common stock, if any, under this prospectus supplement will be made at market prices by any method deemed to be an &ldquo;at
the market offering&rdquo; as defined in Rule&nbsp;415(a)(4)&nbsp;under the Securities Act. During the year ended December&nbsp;31, 2024
through the date hereof, we sold through the Sales Agreement approximately 569,000 shares of our common stock and received net proceeds
of approximately $3.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each time that we wish to issue and sell shares
of our common stock under the Sales Agreement, we will provide the Sales Agent with a placement notice describing the amount of shares
to be sold, the time period during which sales are requested to be made, any limitation on the amount of shares of our common stock that
may be sold in any single day, any minimum price below which sales may not be made or any minimum price requested for sales in a given
time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, the Sales Agent, acting as
our sales agent, will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state
and federal laws, rules&nbsp;and regulations and the rules&nbsp;of the NYSE American, to sell shares of our common stock under the terms
and subject to the conditions of the placement notice and the sales agreement. We or the Sales Agent may suspend the offering of shares
of our common stock pursuant to a placement notice upon notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Settlement for sales of shares of common stock,
unless the parties agree otherwise, will occur on the first trading day following the date on which any sales are made in return for payment
of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.
Sales of shares of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository
Trust Company or by such other means as we and the Sales Agent may agree upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent will be entitled to
compensation at a fixed commission rate of up to 3.0% of the gross proceeds from the sale of shares of our common stock on our
behalf pursuant to the Sales Agreement. Pursuant to the terms of the Sales Agreement, we agreed to reimburse the Sales Agent for the
documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by
the Sales Agreement in an amount not to exceed $50,000 in the aggregate, in addition to up to $10,000 annually for the Sales
Agent&rsquo;s counsel&rsquo;s fees and any incidental expenses to be reimbursed by us. We will report at least quarterly the number
of shares of common stock sold through the Sales Agent under the Sales Agreement, the net proceeds to us and the compensation paid
by us to the Sales Agent in connection with the sales of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the total expenses for this offering,
excluding compensation payable to the Sales Agent and certain expenses reimbursable to the Sales Agent under the terms of the Sales Agreement,
will be approximately $111,000. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed
by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale
of such shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because there are no minimum sale requirements
as a condition to this offering, the actual total public offering price, commissions and net proceeds to us, if any, are not determinable
at this time. The actual dollar amount and number of shares of common stock we sell through this prospectus will be dependent, among other
things, on market conditions and our capital raising requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the sale of shares of common
stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the
compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification
and contribution to the Sales Agent against certain civil liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent will not engage in any market
making activities involving shares of our common stock while the offering is ongoing under this prospectus if such activity would be prohibited
under Regulation M or other anti-manipulation rules&nbsp;under the Securities Act. As our sales agent, the Sales Agent will not engage
in any transactions that stabilizes shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering pursuant to the Sales Agreement
will terminate upon the earlier of (i)&nbsp;the sale of all shares of common stock subject to the Sales Agreement and
(ii)&nbsp;termination of the Sales Agreement as permitted therein. We may terminate the Sales Agreement in our sole discretion at
any time by giving one (1)&nbsp;day&rsquo;s prior notice to the Sales Agent. The Sales Agent may terminate the Sales Agreement under
the circumstances specified in the sales agreement and in its sole discretion at any time by giving five (5)&nbsp;days&rsquo; prior
notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement in electronic format
may be made available on websites maintained by the Sales Agent and the Sales Agent may distribute this prospectus supplement electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Activities and Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sales Agent and certain of its affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The Sales Agent and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and
investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>September&nbsp;2024 Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, on September&nbsp;27, 2024 we consummated
a public offering (the &ldquo;September&nbsp;2024 Offering&rdquo;) of an aggregate of (i)&nbsp;918,600&nbsp;shares (the &ldquo;Shares&rdquo;)
of common stock, (ii)&nbsp;pre-funded warrants (&ldquo;Pre-Funded Warrants&rdquo;) to purchase up to 510,000&nbsp;shares of common stock
(the &ldquo;Pre-Funded Warrant Shares&rdquo;), and (iii)&nbsp;common stock purchase warrants (&ldquo;Common Warrants&rdquo;) to purchase
up to 1,428,600&nbsp;shares of common stock (the &ldquo;Common Warrant Shares&rdquo;). Each Share and associated Common Warrant to purchase
one (1)&nbsp;Common Warrant Share was sold at a combined public offering price of $1.75. Each Pre-Funded Warrant and associated Common
Warrant to purchase one (1)&nbsp;Common Warrant Share was sold at a combined public offering price of $1.7499. The Company received aggregate
gross proceeds from the September&nbsp;2024 Offering of approximately $2.5&nbsp;million, before deducting placement agent fees and other
offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the September&nbsp;2024 Offering,
on September&nbsp;26, 2024, we entered into a placement agency agreement (the &ldquo;Placement Agency Agreement&rdquo;) with A.G.P., as
Placement Agent, pursuant to which the Placement Agent agreed to act as placement agent on a &ldquo;reasonable best efforts&rdquo; basis
in connection with the September&nbsp;2024 Offering. We paid the Placement Agent an aggregate fee equal to 7.0% of the gross proceeds
raised in the September&nbsp;2024 Offering. Further, we agreed to reimburse the Placement Agent up to an aggregate of $100,000 for accountable
legal fees, other reasonable and documented out-of-pocket expenses, and non-accountable expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>May&nbsp;2025 Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;8, 2025, we consummated a public offering
(the &ldquo;May&nbsp;2025 Offering&rdquo;) of an aggregate of (i)&nbsp;1,990,900&nbsp;shares of our common stock, (ii)&nbsp;pre-funded
warrants to purchase up to 4,827,280&nbsp;shares of common stock, and (iii)&nbsp;common stock purchase warrants to purchase up to 6,818,180&nbsp;shares
of common stock. Each share and associated common stock warrant to purchase one shares of common stock was sold at a combined public offering
price of $1.10 and each pre-funded warrant and associated common warrant to purchase one (1)&nbsp;shares of common stock was sold at a
combined public offering price of $1.099. We received aggregate gross proceeds from the May&nbsp;2025 Offering of approximately $7.5&nbsp;million,
before deducting placement agent fees and other offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the May&nbsp;2025 Offering,
on May&nbsp;7, 2025, we entered into a placement agency agreement (the &ldquo;Placement Agency Agreement&rdquo;) with A.G.P./Alliance
Global Partners (the &ldquo;Placement Agent&rdquo;), pursuant to which the Placement Agent agreed to act as placement agent on a &ldquo;reasonable
best efforts&rdquo; basis in connection with the May&nbsp;2025 Offering. We paid the Placement Agent an aggregate fee equal to 7.0% of
the gross proceeds raised in the May&nbsp;2025 Offering. Further, we agreed to reimburse the Placement Agent up to an aggregate of $100,000
for accountable legal fees, other reasonable and documented out-of-pocket expenses, and non-accountable expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of its various business
activities, the Sales Agent and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (including bank loans) for its own account and for the accounts
of its customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates.
If the Sales Agent or its affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent
with their customary risk management policies. The Sales Agent and its affiliates may hedge such exposure by entering into transactions
that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of
our affiliates, including potentially the Common Stock offered hereby. Any such short positions could adversely affect future trading
prices of the Common Stock offered hereby. The Sales Agent and certain of its affiliates may also communicate independent investment recommendations,
market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may
at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="LMS_011"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Blank Rome LLP, New York, New York is representing
us in connection with the offering. The validity of the shares of common stock offered hereby will be passed upon for us by Parsons Behle&nbsp;&amp;
Latimer, Reno, Nevada. Duane Morris LLP, New York, New York is acting as counsel for the Sales Agent in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus supplement,
an attorney of Blank Rome LLP beneficially owns securities exercisable to purchase shares of common stock that represent less than 1%
of our outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ES_012"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Theriva
Biologics,&nbsp;Inc. as of December&nbsp;31, 2024 and 2023 and for each of the two years in the period ended December&nbsp;31, 2024 incorporated
by reference in this prospectus supplement and in the registration statement of which this prospectus supplement forms a part have been
so incorporated in reliance on the report of BDO USA, P.C, an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory paragraph
regarding the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="WYCFMIS_013"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement is part of a registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-279077) we filed with the SEC. This prospectus supplement does not contain all of the information
set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and
the securities we are offering under this prospectus supplement, we refer you to the registration statement, the base prospectus and the
exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any
person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted.
You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page&nbsp;of
this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by
this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at&nbsp;<I>www.sec.gov</I>.
Our SEC filings are also available on our website,&nbsp;<I>www.therivabio.com</I>&nbsp;under the heading &ldquo;Investor Relations&mdash;SEC
Filings.&rdquo; The reference to our website is an inactive textual reference only, the information contained in, and that can be accessed
through our website, is not incorporated into and is not a part of this prospectus. We make available on our website our SEC filings as
soon as reasonably practicable after those reports are filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="IOCDBRS_014"></A><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is considered to be part of this prospectus supplement. Information in this
prospectus supplement supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
supplement, the accompanying base prospectus and the registration statement of which this prospectus supplement is a part the information
or documents listed below that we have filed with the SEC (Commission File No.&nbsp;001-12584):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Annual Report on&nbsp;Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2024 filed with the SEC on March&nbsp;6, 2025;</FONT></A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057825001242/tmb-20250331x10q.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Quarterly Report on&nbsp;Form&nbsp;10-Q&nbsp;for the quarter ended March&nbsp;31, 2025 filed with the SEC on&nbsp;May&nbsp;14, 2025;</FONT></A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Current Reports on Form&nbsp;8-K filed
             with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465925029654/tm2510883d1_8k.htm" STYLE="-sec-extract: exhibit">March&nbsp;31, 2025</A> (other than as set forth therein),&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465925045309/tm2514050d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;7, 2025</A>&nbsp;(other than as set forth
             therein),&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465925046170/tm2514447d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;8, 2025</A>,&nbsp;and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465925055181/tm2516499d1_8k.htm" STYLE="-sec-extract: exhibit">June&nbsp;2, 2025</A> (other than as set forth therein);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT>
 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The description of our common stock set forth
in (i)&nbsp;our registration statements on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016307000379/s11-7491_8a.htm" STYLE="-sec-extract: exhibit">Form&nbsp;8-A12B, filed with the SEC on June&nbsp;20, 2007 (File No.&nbsp;001-12584)</A>&nbsp;and
(ii)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000141057824000293/tmb-20231231xex4d3.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;4.2</A>&mdash;Description of Securities of Theriva Biologics,&nbsp;Inc. to our Annual Report on Form&nbsp;10-K for
the fiscal year ended December&nbsp;31, 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related to
such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&nbsp;of
the Exchange Act, including those made on or after the date of this prospectus supplement but prior to the termination of the offering
(i.e., until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement
of which this prospectus supplement forms a part has been withdrawn). Information in such future filings updates and supplements the information
provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede
any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference
to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus supplement but not delivered with the prospectus supplement, including exhibits that are
specifically incorporated by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Theriva Biologics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>9605 Medical Center Drive, Suite&nbsp;270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, Maryland 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Telephone: (301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Attention: Corporate Secretary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of charge,
on the SEC&rsquo;s website at&nbsp;<I>www.sec.gov</I>&nbsp;or on our website at&nbsp;<I>https://ir.therivabio.com/sec-filings</I>. The
information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus
supplement and the accompanying base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus supplement and the accompanying base prospectus. We have not authorized anyone
to provide you with information different from that contained in this prospectus supplement or incorporated by reference into this prospectus
supplement. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized
or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an
offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2518361d1_424b5img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THERIVA BIOLOGICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may, from time to time, offer and sell up to
$200,000,000 of any combination of our common stock, par value $0.001 (the &ldquo;common stock&rdquo;), preferred stock, par value $0.001
(the &ldquo;preferred stock&rdquo;), debt securities, warrants or units described in this prospectus, either individually or in combination
with other securities, at prices and on terms described in one or more supplements to this prospectus. We may also offer common stock
or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock,
or debt securities upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus provides you with a general description
of the securities that we may offer. Each time we offer and sell securities, we will <FONT STYLE="background-color: white">provide a supplement
to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. </FONT>We
may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement
and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully
read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated
by reference, before buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale,
you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus and in the applicable prospectus supplement.
<FONT STYLE="background-color: white">If any underwriters, dealers or agents are involved in the sale of any of the securities, their
names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable
from the information set forth, in the applicable prospectus supplement. </FONT>The price to the public of such securities and the net
proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. <FONT STYLE="background-color: white">No
securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of
the offering of such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the NYSE American
LLC under the symbol &ldquo;TOVX.&rdquo; On September&nbsp;23, 2024, the last reported sale price of our common stock on the NYSE American
LLC was $3.42 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if
any, on any securities market or other exchange of the specific security covered by such prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates is approximately $9,806,578, which is calculated based on 1,353,565
shares of our outstanding common stock held by non-affiliates and a price of $7.245 per share, the closing price of our common stock on
July&nbsp;24, 2024, which is the highest closing sale price of our common stock on the NYSE American LLC within the prior 60 days of this
prospectus. During the prior twelve calendar month period that ends on and includes the date hereof, we have offered and sold approximately
$3,738,514 of shares of our common stock pursuant to General Instruction I.B.6 to Form&nbsp;S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; beginning
on page&nbsp;6 of this prospectus and contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized
for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into
this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is September&nbsp;25,
2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#ATP_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#ATP_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#PS_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#PS_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#RF_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#RF_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#FLS_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#FLS_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#UOP_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#UOP_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#DOCS_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOCS_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#DODS_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Debt Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DODS_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#DOW_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Warrants</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOW_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#DOU_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Units</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#DOU_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#LOS_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Ownership of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#LOS_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#POD_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#POD_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#LM_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#LM_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#E_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#E_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#WTCFMI_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#WTCFMI_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#IOCBR_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#IOCBR_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="ATP_015"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
on Form&nbsp;S-3 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration
process. Under this shelf registration statement, we may sell from time to time in one or more offerings up to a total dollar amount of
$200,000,000 of shares of common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such securities,
either individually or as units in combination with other securities as described in this prospectus. Each time we sell any type or series
of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms
of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information
relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to
you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference
into this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in
this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in a prospectus supplement.
You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together
with the additional information described under &ldquo;Where You Can Find More Information,&rdquo; before buying any of the securities
being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS PROSPECTUS MAY&nbsp;NOT BE USED TO CONSUMMATE
A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we, nor any agent, underwriter or dealer
has authorized any person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which
we have referred you. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any
applicable supplement to this prospectus or any related free writing prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any applicable
supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not assume that the information contained
in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to
the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent
to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related
free writing prospectus is delivered, or securities are sold, on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a
part, and you may obtain copies of those documents as described below under the section entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated herein or as the
context otherwise requires, references in this prospectus to &ldquo;Theriva,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
 &ldquo;our&rdquo; and similar references refer to Theriva Biologics,&nbsp;Inc., an entity incorporated under the laws of the State of
Nevada, and where appropriate our consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the information incorporated
herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and
trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing
prospectus are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="PS_016"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights information
contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may be important
to purchasers of our securities. Prospective purchasers of our securities should carefully read the entire prospectus, the applicable
prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the
heading &ldquo;Risk Factors&rdquo; contained in this prospectus, the applicable prospectus supplement and any related free writing prospectus,
and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective purchasers of our
securities should also carefully read the information incorporated by reference into this prospectus, including our financial statements,
and the exhibits to the registration statement of which this prospectus is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a diversified clinical-stage company developing
therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the acquisition in March&nbsp;2022
(the &ldquo;Acquisition&rdquo;) of Theriva Biologics, S.L. (&ldquo;VCN&rdquo;, formerly named VCN Biosciences, S.L.), we began transitioning
our strategic focus to oncology, which is now our primary focus, through the development of VCN&rsquo;s new oncolytic adenovirus platform
designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies
to the tumor, and to promote a robust and sustained anti-tumor response by the patient&rsquo;s immune system. Our lead product candidate,
VCN-01, a clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express an enzyme, PH20 hyaluronidase,
is currently being evaluated in a Phase 2 clinical study for the treatment of pancreatic cancer (&ldquo;Virage&rdquo;), and has recently
been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma, and Phase 1 clinical studies for the treatment
of other solid tumors including head and neck squamous cell carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Acquisition, our focus was on developing
therapeutics designed to treat gastrointestinal (GI) diseases which included our clinical development candidates: (1)&nbsp;SYN-004 (ribaxamase)
which is designed to degrade certain commonly used intravenous (IV)&nbsp;beta-lactam antibiotics within the GI tract to prevent microbiome
damage, thereby preventing overgrowth and infection by pathogenic organisms such&nbsp;<I>Clostridioides difficile</I>&nbsp;infection (CDI)
and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic
hematopoietic cell transplant (HCT) recipients, and (2)&nbsp;SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline
phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. As part of our strategic transformation
into an oncology focused company, we are exploring value creation options for our SYN-004 and SYN-020 assets, including out-licensing
or partnering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Current Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2518361d1_424b5img003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>*Based on management&rsquo;s current beliefs and expectations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>allo-HCT&nbsp;</B>allogeneic hematopoietic
cell transplant.&nbsp;<B>CPI&nbsp;</B>immune checkpoint inhibitor.&nbsp;<B>CSR</B>&nbsp;clinical study report.&nbsp;<B>FTD</B>&nbsp;Fast
Track Designation.<B>&nbsp;HNSCC</B>&nbsp;head and neck squamous cell carcinoma.&nbsp;<B>IV&nbsp;</B>intravenous.<B>&nbsp;IVit&nbsp;</B>intravitreal.<B>&nbsp;ODD&nbsp;</B>Orphan
Drug Designation.<B>&nbsp;</B>For other abbreviations see the text.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&sup1; Additional products with preclinical proof-of-concept include
SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterococci and SYN-007 (ribaxamase) DR to prevent antibiotic
associated diarrhea with oral &beta;-lactam antibiotics.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&sup2; Depending on funding/partnership. SYN-004
may enter an FDA-agreed Phase 3 clinical trial for the treatment of CDI.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><B><I>Reverse
Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">On August&nbsp;26,
2024, we effected a reverse stock split of our authorized, issued and outstanding shares of common stock at a ratio of one (1)&nbsp;share
of common stock for every twenty-five (25) shares of common stock (the &ldquo;Reverse Stock Split&rdquo;) and the common stock began trading
on the NYSE American on a post-split basis when the market opened on August&nbsp;26, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">As a
result of the Reverse Stock Split, each twenty-five (25) shares of common stock outstanding automatically combined into one (1)&nbsp;new
share of common stock without any action on the part of the holders, and the number of outstanding shares common stock was reduced from
25,131,230 shares to 1,005,249 shares (subject to rounding of fractional shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">No fractional
shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares
because they hold a number of pre-Reverse Stock Split shares of common stock not evenly divisible by 25 ware, in lieu of a fractional
share, automatically be entitled to receive an additional fractional share of the common stock to round up to the next whole number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">The Reverse
Stock Split was effected to meet the per share price requirements of the NYSE American, the securities exchange on which the common stock
is listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">After
the Reverse Stock Split, the trading symbol for the common stock continued to be &ldquo;TOVX.&rdquo; The new CUSIP number for the common
stock following the Reverse Stock Split is&nbsp;<FONT STYLE="background-color: white">87164U 508</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our predecessor, Sheffield
Pharmaceuticals,&nbsp;Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics,&nbsp;Inc., a publicly-traded
Delaware corporation formed in 2001. After the reverse merger, we changed our name to Pipex Pharmaceuticals,&nbsp;Inc., and in October&nbsp;2008
we changed our name to Adeona Pharmaceuticals,&nbsp;Inc. On October&nbsp;15, 2009, we engaged in a merger with a wholly owned subsidiary
for the purpose of reincorporating in the State of Nevada. On February&nbsp;15, 2012, we changed our name to Synthetic Biologics,&nbsp;Inc.
On August&nbsp;10, 2018, we effected a one for thirty-five reverse stock split of our authorized, issued and outstanding common stock.
On July&nbsp;15, 2022, we effected a one for ten reverse stock split of our authorized, issued and outstanding common stock. On October&nbsp;12,
2022, we changed our name to Theriva Biologics,&nbsp;Inc. On August&nbsp;26, 2024, we effected the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
9605 Medical Center Drive, Suite&nbsp;270, Rockville, Maryland 20850, and our telephone number is (301) 417 - 4367. Our website address
is <I>www.therivabio.com</I>. <FONT STYLE="background-color: white">Information contained on our website is intended for informational
purposes only and is not incorporated by reference into this prospectus, and it should not be considered to be part of this prospectus
or the </FONT>registration statement of which this prospectus forms a part. The SEC maintains an internet site that contains reports,
proxy and information statements, and other information regarding issuers like us that file documents electronically with the SEC. The
address of the SEC website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a &ldquo;smaller reporting company&rdquo;
as defined in the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). As a result, we may take advantage of
certain reduced disclosure obligations available to smaller reporting companies, including the exemption from compliance with the auditor
attestation requirements pursuant to the Sarbanes-Oxley Act of 2022, reduced disclosure about our executive compensation arrangements
and the requirements to provide only two years of audited financial statements in our annual reports and registration statements. We will
continue to be a &ldquo;smaller reporting company&rdquo; as long as (1)&nbsp;we have a public float (i.e., the market value of our common
stock held by non-affiliates) less than $250 million calculated as of the last business day of our most recently completed second fiscal
quarter, or (2)&nbsp;our annual revenues are less than $100 million for our previous fiscal year and we have either no public float or
a public float of less than $700 million as of the end of that fiscal year&rsquo;s second fiscal quarter. Decreased disclosures in our
SEC filings due to our status as a &ldquo;smaller reporting company&rdquo; may make it harder for investors to analyze our results of
operations and financial prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated with our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to numerous risks, as
described under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement and in any free writing prospectuses
we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by
reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Securities We May&nbsp;Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer shares of our common stock, preferred
stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or as units in combination
with other securities, with a total value of up to $200,000,000 from time to time under this prospectus at prices and on terms to be determined
at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer
a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts,
prices and other important terms of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designation or classification;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">aggregate principal amount or aggregate offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maturity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">original issue discount;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rates and times of payment of interest or dividends;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redemption, conversion, exercise, exchange or sinking fund terms;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ranking;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictive covenants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting or other rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conversion or exchange prices or rates and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of material United States federal income tax considerations, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security
that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus
is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the securities directly to investors
or to or through agents, underwriters or dealers. We, and our agents, underwriters or dealers reserve the right to accept or reject all
or part of any proposed purchase of securities. If we do offer securities to or through agents, underwriters or dealers, we will include
in the applicable prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names of those agents, underwriters, or dealers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable fees, discounts and commissions to be paid to them;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">details regarding over-allotment options, if any; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the net proceeds to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the securities we
may offer with this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our common stock from time
to time. Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. Under our articles of incorporation, as amended (the &ldquo;Articles of Incorporation&rdquo;) and
second amended and restated bylaws (the &ldquo;Bylaws&rdquo;), our stockholders do not have cumulative voting rights. Subject to preferences
that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends,
if any, as may be declared from time to time by the board of directors out of legally available funds. In the event of our liquidation,
dissolution or winding up, holders of common stock are entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted
to the holders of any then-outstanding shares of preferred stock. Holders of shares of our common stock do not have preemptive, subscription,
redemption, or conversion rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences
and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of
any series of preferred stock that we may designate in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue shares of our preferred stock from
time to time, in one or more series. Our board of directors will determine the designations, voting powers, preferences and rights of
the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights,
preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting
any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for
other securities. Conversion may be mandatory or at the holder&rsquo;s option and would be at prescribed conversion rates. If we sell
any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series
of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to
that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference
from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred
stock that we are offering before the issuance of the related series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to read the applicable prospectus
supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being
offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Debt Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities
will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in
right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible
debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at your
option and would be at prescribed conversion rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any debt securities issued under this prospectus
will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other
eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however,
to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to
the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form
of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures
and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement
of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue warrants for the purchase of common
stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or as units in combination with
common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus,
we have summarized certain general features of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you, however, to read the applicable prospectus
supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of warrants being offered,
as well as any warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant
and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are
offering, and any supplemental agreements, before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any warrants issued under this prospectus may
be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into with a warrant
agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular
series of warrants being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating
to a particular series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, we have summarized certain
general features of the units under &ldquo;Description of Units.&rdquo; We urge you, however, to read the applicable prospectus supplement
(and any related free writing prospectus that we may authorize to be provided to you) related to the series of units being offered, as
well as the complete unit agreement that contains the terms of the units. We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the specific unit agreement that contains
the terms of the particular series of units we are offering, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RF_017"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high degree
of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties described under
the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement and any related free writing prospectus, and
discussed under the section entitled &ldquo;Risk Factors&rdquo; contained in our most recent Annual Report on Form&nbsp;10-K, our most
recent Quarterly Reports on Form&nbsp;10-Q, as such filings may be updated by subsequent annual, quarterly and other reports that are
incorporated by reference into this prospectus in their entirety. The risks described in these documents are not the only ones we face,
but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or
other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator
of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks
actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the
trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section
below entitled &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="FLS_018"></A><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus, including the documents that
we incorporate by reference herein, contains, and any applicable prospectus supplement or free writing prospectus including the documents
we incorporate by reference therein may contain, forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section&nbsp;21E of the Exchange Act, including statements regarding our future
financial condition, business strategy and plans and objectives of management for future operations. Forward-looking statements include
all statements that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as &ldquo;believe,&rdquo;
 &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;might,&rdquo; &ldquo;approximately,&rdquo; &ldquo;expect,&rdquo; &ldquo;predict,&rdquo;
 &ldquo;could,&rdquo; &ldquo;potentially&rdquo; or the negative of these terms or other similar expressions. Forward-looking statements
include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discussions containing these forward-looking statements
may be found, among other places, in the sections entitled &ldquo;Business,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; contained in the documents incorporated by reference herein,
including our most recent Annual Report on Form&nbsp;10-K and our Quarterly Reports on Form&nbsp;10-Q and our Current Reports on Form&nbsp;8-K,
as well as any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results,
levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements.
We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties
under the heading &ldquo;Risk Factors&rdquo; contained in the applicable prospectus supplement, in any free writing prospectus we may
authorize for use in connection with a specific offering, and in the documents incorporated by reference herein. These statements reflect
our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. We undertake no obligation
to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="UOP_019"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will retain broad discretion over the use of
the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus supplement or in any related free
writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the securities
offered by us hereunder primarily for working capital and general corporate purposes. We will set forth in the applicable prospectus supplement
or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus
supplement or free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DOCS_020"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is a description of the material
terms of our capital stock. This is a summary only and does not purport to be complete. It is subject to and qualified in its entirety
by reference to our Articles of Incorporation and our Bylaws, each of which are incorporated by reference as an exhibit to the registration
statement of which this prospectus forms a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable
provisions of the Nevada Revised Statute (the &ldquo;NRS&rdquo;), for additional information.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,000,000 shares of common stock, par value $0.001 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000 shares of preferred stock, par value $0.001 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Outstanding Shares</I>. As of September&nbsp;9,
2024, there were 1,353,565 shares of our common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I>. The holders of the common
stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election
of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of the common stock entitled
to vote in any election of directors can elect all of the directors standing for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividend Rights</I>. Subject to preferences
that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any,
as may be declared from time to time by our board of directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I>. In the event of our
liquidation, dissolution or winding up, holders of the common stock will be entitled to share ratably in the net assets legally available
for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation
preference granted to the holders of any then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Rights and Preferences</I>. The holders
of the common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of the common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully Paid and Nonassessable</I>. All of our
outstanding shares of common stock are fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of terms of our preferred
stock is not complete. We will file as an exhibit to the registration statement of which this prospectus is a part or will incorporate
by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series
of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred
stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, without further action
by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred
stock in one or more series and authorize their issuance. There are no shares of preferred stock designated or outstanding. These rights,
preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater
than the rights of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors will fix the designations,
voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications,
limitations or restrictions thereof, in the certificate of designation relating to that series. We will describe in the applicable prospectus
supplement the terms of the series of preferred stock being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title and stated value;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares we are offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the liquidation preference per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend rate, period and payment date and method of calculation for dividends;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the procedures for any auction and remarketing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for a sinking fund;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any listing of the preferred stock on any securities exchange or market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting rights of the preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preemptive rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on transfer, sale or other assignment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether interests in the preferred stock will be represented by depositary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of material United States federal income tax considerations applicable to the preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of NRS, our Articles of Incorporation
and our Bylaws described below may have the effect of delaying, deferring or discouraging another party from acquiring control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;business combination&rdquo; provisions
of Sections 78.411 to 78.444, inclusive, of the NRS generally prohibit a Nevada corporation with at least 200 stockholders from engaging
in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date the
interested stockholder obtained such status or the combination is approved by the board of directors and thereafter is approved at a meeting
of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested
stockholders, and extends beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; padding-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the combination was approved by the board of directors prior to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (b)&nbsp;the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c)&nbsp;for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;combination&rdquo; is generally defined
to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction
or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a)&nbsp;an aggregate market value equal to 5% or more
of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to 5% or more of the aggregate
market value of all outstanding shares of the corporation, (c)&nbsp;10% or more of the earning power or net income of the corporation,
and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;control share&rdquo; provisions of
Sections 78.378 to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with at least
200 stockholders, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly
in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&rsquo;s
stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s disinterested
stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and
a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in
an offer or acquisition and acquired within 90 days thereof become &ldquo;control shares&rdquo; and such control shares are deprived of
the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded
full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote
in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance
with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A corporation may elect to not be governed by,
or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that
the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that
is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject to
these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effect of the Nevada control share statutes
is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Articles of Incorporation and Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the authorized number of directors is determined by our board of directors;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directors may be removed only by the affirmative vote of the holders of at least a majority of our voting stock, whether for cause or without cause;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Bylaws may be amended or repealed by our board of directors or by the affirmative vote of our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">special meetings of the stockholders may be called by Chairman of the board, if any, the Vice Chairman of the board, if any, or the President or upon request of stockholders owning a majority of the outstanding shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors may fill vacancies on the board of directors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our board of directors will be authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders do not have cumulative voting rights, and therefore our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stockholders must comply with advance notice provisions to bring business before or nominate directors for election at a stockholder meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Potential Effects of Authorized but Unissued
Stock</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have shares of common stock available for future
issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public
offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of unissued and unreserved common
stock may enable our board of directors to issue shares to persons friendly to current management.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Director Liability and Indemnification
of Directors, Officers and Employees</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.138 provides that directors of a corporation
is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act
in his or her capacity as a director or officer unless: (a)&nbsp;the presumption that directors and officers acted in good faith on an
informed basis with a view toward the best interest of the corporation has been rebutted and (b)&nbsp;it is proven that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The director&rsquo;s or officer&rsquo;s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such breach involved intentional misconduct, fraud or a knowing violation of law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation and Bylaws provide
that we will indemnify our directors and officers to the fullest extent permitted by law and may indemnify employees and other agents.
Our Articles of Incorporation also provide that we are obligated to advance expenses incurred by a director or officer in advance of the
final disposition of any action or proceeding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have obtained a policy of directors&rsquo;
and officers&rsquo; liability insurance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into separate indemnification
agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors and officers for
any and all expenses (including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts, witness fees,
travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments, fines and
amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection with any
action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other company
or enterprise to which the person provides services at our request provided that such person follows the procedures for determining entitlement
to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability and indemnification
provisions in our Articles of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed that, in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At present, there is no pending litigation or proceeding involving
any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation
or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing of the Common Stock on the NYSE American
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed for trading on the
NYSE American LLC under the symbol &ldquo;TOVX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock is Equiniti Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&nbsp;9, 2024, we had options outstanding
to purchase an aggregate of 175,191 shares of common stock that were issued under our equity compensation plans. As of September&nbsp;9,
2024, there were 112,640 shares of common stock reserved for future issuance under our equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September&nbsp;9, 2024, there are no shares
of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DODS_021"></A><B>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized
below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any
debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under
a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture,
we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will issue the debt securities under the indenture
that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939,
as amended (the &ldquo;Trust Indenture Act&rdquo;). We have filed the form of indenture as an exhibit to the registration statement of
which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference
from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of material provisions of
the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture
applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any related free writing
prospectus related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the
terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indenture will not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be
in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially
all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to
give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue the debt securities issued under
the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at a discount below their stated principal amount. These
debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original issue discount,&rdquo;
or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material
U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title of the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any limit upon the aggregate principal amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the maturity date or dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the form of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicability of any guarantees;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&rsquo; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #0070C0"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: Black">&middot;</FONT>
 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions upon which the election may be made;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities.
We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option
of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities
that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability
to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety.
However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture
or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an event of default with respect to debt securities
of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders
of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and
payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of
and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action
on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of a majority in principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its
consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured
the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of the indenture, if an event
of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or
powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such
holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities
of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee,
or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only
if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and the trustee may change an indenture without
the consent of any holders with respect to specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with the provisions described above under &ldquo;Description of Debt Securities&mdash;Consolidation, Merger or Sale;&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &ldquo;Description of Debt Securities&mdash;General&rdquo; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under the indenture, the rights of
holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority
in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only
with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending the fixed maturity of any debt securities of any series;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each indenture provides that we can elect to be
discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide for payment;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register the transfer or exchange of debt securities of the series;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">replace stolen, lost or mutilated debt securities of the series;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay principal of and premium and interest on any debt securities of the series;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain paying agencies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hold monies for payment in trust;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recover excess money held by the trustee;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensate and indemnify the trustee; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoint any successor trustee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest
on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will issue the debt securities of each series
only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations
of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent
global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another
depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities
of a series are issued in global form and as book-entry, a description of terms relating such securities will be set forth in the applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the option of the holder, subject to the terms
of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination
and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of the indenture and the
limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present
the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed
if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated
by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will name in the applicable prospectus supplement
the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities.
We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office
through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt
securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we elect to redeem the debt securities of any
series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the
applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would
exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any
of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity
against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose
name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for
the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay principal of and any premium and interest
on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate
in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to
certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of
the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus
supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying
agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All money we pay to a paying agent or the trustee
for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after
such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may
look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The indenture and the debt securities will be
governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture
Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DOW_022"></A><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description, together with the additional
information we may include in any applicable prospectus supplement and in any related free writing prospectus, summarizes the material
terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock,
preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or in combination with
common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply
generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in
more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this
prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular
series of warrants may specify different or additional terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed or will file forms of the warrant
agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration
statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements,
before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified
in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as
applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We
urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus,
as well as any related free writing prospectus, and the complete form of warrant and/or the warrant agreement and warrant certificate,
as applicable, and any supplemental agreements, that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and aggregate number of warrants offered;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the currency for which the warrants may be purchased;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on and after which the warrants and the related securities will be separately transferable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dates on which the right to exercise the warrants will commence and expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manner in which the warrant agreements and warrants may be modified;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of material United States federal income tax consequences of holding or exercising the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the securities issuable upon exercise of the warrants; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before exercising their warrants, holders of warrants
will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant will entitle the holder to purchase
the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at
any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of
business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant or warrant certificate representing
the warrants to be exercised together with specified information, and paying the required amount to the warrant agent, if applicable,
in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of any warrant
certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to
any warrant agent in connection with the exercise of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon receipt of payment and the warrant or warrant
certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other
office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable
upon such exercise. If fewer than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant
or a new warrant certificate, as applicable, will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants
or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant agent, if any, will act solely as
our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the
related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities
purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="DOU_023"></A><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description, together with the additional
information we may include in any applicable prospectus supplement and related free writing prospectus, summarizes the material terms
and provisions of the units that we may offer under this prospectus. We may issue units consisting of any combination of the other types
of securities offered under this prospectus in one or more series. We will issue each unit so that the holder of the unit is also the
holder of each security included in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each
included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of any unit agent in the applicable prospectus supplement relating
to a particular series of units. The summary below and that contained in any prospectus supplement is qualified in its entirety by reference
to all of the provisions of the unit agreement and/or unit certificate, and depositary arrangements, if applicable. We urge you to read
the applicable prospectus supplements and any related free writing prospectuses related to the units that we may offer under this prospectus,
as well as the complete unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of
the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will file as exhibits to the registration statement
of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement
and/or unit certificate, and depositary arrangements, as applicable, that contain the terms of the particular series of units we are offering,
and any supplemental agreements, before the issuance of such units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will describe in the applicable prospectus
supplement the terms of the series of units being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the units will be issued in fully registered or global form; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other terms of the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="LOS_024"></A><B>LEGAL OWNERSHIP OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can issue securities in registered form or
in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have
securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this
purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We refer to those persons
who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &ldquo;indirect
holders&rdquo; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in
book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Book-Entry Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue securities in book-entry form only,
as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities
registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate
in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial
interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only the person in whose name a security is registered
is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants.
Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments
on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the
payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have
made with one another or with their customers; they are not obligated to do so under the terms of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, investors in a global security will
not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial
institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant. As long as the securities
are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may terminate a global security or issue securities
that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &ldquo;street
name.&rdquo; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution
that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains
at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For securities held in street name, we or any
applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the
securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those
securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only
because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities
in street name will be indirect holders, not holders, of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligations, as well as the obligations of
any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations
to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case
whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, once we make a payment or give a
notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with
its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain
the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with
a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and
not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Considerations for Indirect Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you hold securities through a bank, broker
or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in
street name, you should check with your own institution to find out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how it handles securities payments and notices;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether it imposes fees or charges;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how it would handle a request for the holders&rsquo; consent, if ever required;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the securities are in book-entry form, how the depositary&rsquo;s rules&nbsp;and procedures will affect these matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Securities</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities
will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that
we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable
prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued
in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A global security may not be transferred to or
registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations
arise. We describe those situations below under &ldquo;&mdash;Special Situations When a Global Security Will Be Terminated.&rdquo; As
a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented
by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must
be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with
another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security at
all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry
clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations for Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an indirect holder, an investor&rsquo;s rights
relating to a global security will be governed by the account rules&nbsp;of the investor&rsquo;s financial institution and of the depositary,
as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead
deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are issued only as global securities,
an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depositary&rsquo;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&rsquo;s interest in the global security;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions that participate in the depositary&rsquo;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Situations When a Global Security Will
Be Terminated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a few special situations described below, a
global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that
exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their
own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct
holders. We have described the rights of holders and street name investors above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless we provide otherwise in the applicable
prospectus supplement, a global security will terminate when the following special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we notify any applicable trustee that we wish to terminate that global security; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable prospectus supplement may also
list additional situations for terminating a global security that would apply only to the particular series of securities covered by the
applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible
for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="POD_025"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the securities from time to time pursuant
to underwritten public offerings, direct sales to the public, &ldquo;at the market&rdquo; offerings, negotiated transactions, block trades
or a combination of these methods. We may sell the securities to or through one or more underwriters or dealers (acting as principal or
agent), through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a fixed price or prices, which may be changed;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at market prices prevailing at the time of sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at prices related to such prevailing market prices; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name or names of the underwriters, dealers, agents or other purchasers, if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price of the securities or other consideration therefor, and the proceeds we will receive from the sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any option to purchase additional shares or other options under which underwriters, dealers, agents or other purchasers may purchase additional securities from us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any agency fees or underwriting discounts to be allowed or paid to the agent or underwriters and other items constituting agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any public offering price;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any securities exchange or market on which the securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of the
securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting
discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If underwriters are used in the sale, they will
acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will
be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting
syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters
will be obligated to purchase all of the securities offered by the prospectus supplement other than securities covered by any option to
purchase additional shares or other option. If a dealer is used in the sale of securities, we, or an underwriter, will sell the securities
to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer
at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of
the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time
to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement,
naming the underwriter, dealer or agent, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions
we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts
basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may authorize agents or underwriters to solicit
offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe
the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may provide agents, dealers and underwriters
with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents, dealers or underwriters may make with respect to these liabilities. Agents, dealers and underwriters or their affiliates
may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All securities we may offer, other than common
stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but
will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any underwriter may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create
a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed
a specified maximum price. Syndicate covering or other short-covering transactions involve purchases of the securities, either through
exercise of the option to purchase additional shares or in the open market after the distribution is completed, to cover short positions.
Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the
dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities
to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions
may be effected on any exchange or over-the-counter market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any underwriters, dealers or agents that are qualified
market makers on the NYSE American LLC may engage in passive market making transactions in our common stock on the NYSE American LLC in
accordance Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement
of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent
bid for such security; if all independent bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities
at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The specific terms of any lock-up provisions in respect of any given
offering will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The anticipated date of delivery of offered securities
will be set forth in the applicable prospectus supplement relating to each offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="LM_026"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The validity
of the shares of common stock being offered by this prospectus is being passed upon by&nbsp;</FONT>Parsons Behle&nbsp;&amp; Latimer, Reno,
Nevada. Blank Rome LLP, New York, New York has acted as securities counsel to Theriva Biologics,&nbsp;Inc.&nbsp; Additional legal matters
may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
A partner of Blank Rome LLP has options to purchase shares of stock of Theriva Biologics,&nbsp;Inc. that represent less than 1% of the
outstanding shares of common stock of Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="E_027"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Theriva
Biologics,&nbsp;Inc. as of December&nbsp;31, 2023 and 2022 and for each of the two years in the period ended December&nbsp;31, 2023 incorporated
by reference in this prospectus and in the registration statement of which this prospectus forms a part have been so incorporated in reliance
on the report of BDO USA, P.C, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding the Company's ability
to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="WTCFMI_028"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any
agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as
of any date other than the date on the front page&nbsp;of this prospectus, regardless of the time of delivery of this prospectus or any
sale of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at <I>www.sec.gov</I>.
Our SEC filings are also available on our website, <I>www.therivabio.com</I> under the heading &ldquo;Investor Relations&mdash;SEC Filings.&rdquo;
The reference to our website is an inactive textual reference only, the information contained in, and that can be accessed through our
website, is not incorporated into and is not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably
practicable after those reports are filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="IOCBR_029"></A><B>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus
supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the
SEC (Commission File No.&nbsp;001-12584):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000293/tmb-20231231x10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023 filed with the SEC on March&nbsp;25, 2024;</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824000601/tmb-20240331x10q.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on Form&nbsp;10-Q for the fiscal quarter ended March&nbsp;31, 2024 filed with the SEC on May&nbsp;7, 2024;</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000141057824001342/tmb-20240630x10q.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on Form&nbsp;10-Q for the fiscal quarter ended June&nbsp;30, 2024 filed with the SEC on August&nbsp;13, 2024;</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on
    Form&nbsp;8-K filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924011395/tm245387d1_8k.htm" STYLE="-sec-extract: exhibit">February&nbsp;7,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050037/tm2412300d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;22,
    2024</A> (other than as set forth therein),&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;23,
    2024</A>&nbsp;(other than as set forth therein) and&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924056146/tm2413223d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;2,
    2024</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924062270/tm2414630d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;16,
    2024</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924064544/tm2415354d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;23,
    2024</A>, (other than as set forth therein) <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924084159/tm2420486d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;31, 2024</A>&nbsp;(other than as set forth therein),&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924090522/tm2421949d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;16, 2024</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924092644/tm2422579d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;26, 2024</A>&nbsp;and&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/894158/000110465924098225/tm2423567d1_8k.htm" STYLE="-sec-extract: exhibit">September&nbsp;9, 2024</A>; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock set forth in (i)&nbsp;our registration statements on <A HREF="https://www.sec.gov/Archives/edgar/data/894158/000089016307000379/s11-7491_8a.htm" STYLE="-sec-extract: exhibit">Form&nbsp;8-A12B, filed with the SEC on June&nbsp;20, 2007 (File No.&nbsp;001-12584)</A> and (ii)&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/894158/000141057824000293/tmb-20231231xex4d3.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;4.3</A>&mdash;Description of Securities to our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form&nbsp;8-K and exhibits filed on such form that are related to
such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)&nbsp;of
the Exchange Act, including those made (i)&nbsp;on or after the date of the filing of the registration statement of which this prospectus
forms a part and prior to effectiveness of such registration statement, and (ii)&nbsp;on or after the date of this prospectus but prior
to the termination of the offering (i.e., until the earlier of the date on which all of the securities registered hereunder have been
sold or the registration statement of which this prospectus forms a part has been withdrawn). Information in such future filings updates
and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to
modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated
herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Theriva Biologics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9605 Medical Center Drive, Suite&nbsp;270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of charge,
on the SEC&rsquo;s website at&nbsp;<I>www.sec.gov</I>&nbsp;or on our website at&nbsp;<I>https://ir.therivabio.com/sec-filings</I>. The
information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus
or any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule&nbsp;412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference into this prospectus. We are not making offers
to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2518361d1_424b5img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $2,534,352 of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>A.G.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June&nbsp;20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2518361d1_424b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2518361d1_424b5img001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ ,@# 2(  A$! Q$!_\0
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ME5DFXM037BX_/\/EN/JRQ%-/"X;+HRJJ,5%*HJ'O3:BG>?->;DDU>.B^%/\
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M&C*K)TTVUSSOS1NI)^ZM$DY*U]-M=]I1C347.2CS;7DDK=-G_P '>Z- 3$G
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M1>%-9T+PQ96#:M/I.CZ%X4GGTRT6+[<S3V=U/)JEU%# 2%46[R*(VW;&!V_
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MH]K\4?B?:RZUX+@G<:C-<Z%H^JZ=8L@6[E:].DRW=Q9V@B C%Y<F&+:I:.0
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&>K?5G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2518361d1_424b5img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2518361d1_424b5img002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E KP# 2(  A$! Q$!_\0
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M*/!6K^ ?">N6FD:)XC&BQZ?::E::W?ZE_HMU:S?;+J272I5=;58E]_\ A?\
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M5_,#/@-)N-ON9B% +$Y.T#/%?:_]A:9_T#[/_OS;_P#Q-(?#^DM]_3;(]O\
M4P=.O0(??TYK1YEP]URK.FNO^V2>G;6D[^G_  Y']F^(4M\XX?W3_P!QW:^;
MU]/,^)_^'@G[,Q1(SJVOL(VWHS>&=89U<L6,BR&WWJ^22'#9&2,XI3_P4%_9
MG8Y;5]?W!&59!X9U=9%#DF0K(+?<'<_>=2&8C#&OM7_A'M)_Z!MI_P!^K;_X
MW1_PCVD_] VT_P"_5M_\;H_M'AW6^4YSK>_^V[WU?_+CO\O+N_[,\0?^AQP]
M_P"$4?PU\SXH'_!0#]F4-O35?$ =FC=Y!X9UD23/$H16G<6^^<A%529&8L%
M)X%3G_@H/^S9A1_:_B-<3";*>&];3<RC +%8!O7: "C91@!D8 K[1_X1[21_
MS#[,GVAMQ_[3_/!H_P"$?TK_ *!UKZ_ZJV^O_/.IEC^'*D7&>49Q*+27+/&-
MJRLU>+H=&E;72VEK))4\L\0:4N>EG&04Y._O0P*BW>]];J[=[.][W?4^-?\
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M[+37'?E^J/DH_P#!27]E,L&/BW5<@Y'_ !(-4P&[.!]GP'7^!_OKQM(J,_\
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MU$E4R#/)J/PJ>*KR4;7M9/!.UKO;O966@1R_Q*A\&>\-0_PX&$>M^C1\.O\
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MLO\ P'M?_B*IYEPW+?*,X?KBI/\ ]Q??W".4^(\7>.<Y%%]U@+/ONFNI\/\
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M']("Y.G64FWD"2S@< @\$;H\ DX(.,_ESTEB$C@V+@ .^   !R. % 4 'H
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M00 -K$X#<DCH,-G@CVZ9P3_JG]"/+LIQ'@O@,5C*</:8O%<3PK1Q^3+%SE#
MXJHL,X3Q,YN/)=N7)9U&[2=XG\!_2-K8RGXDXC#4,1F,W3473EAZ^)A2A)P@
M_>A3?LY6;M:2WWNC:_X2#6\DC5]1P>0#=/D#@$<N3P,GT XX' 3_ (2#6_\
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MW;CLP':G?9V_OC_Q[_XJK$8P@ ]_YFGUX+IIMMSK7;Z5JB7W*6A[2Y?Y*?\
MX+B5/L[?WQ_X]_\ %4?9V_OC_P >_P#BJMT4O9+^>M_X/J__ "06C_S[I_\
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MF<28Q7W&7XO+JN'@L7G^<8&I!TW[+#8-XJC)QYX*FZCY51A&DJ:C.,I-MO\
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M'N=$TK6O&=W=>,KGP_I,UI<6=EI.E-X@EOULK+3C,T\"6HC\IW'?)/E^C?\
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M_GTF_P#!CJ7_ ,DT?\()X9_Y])O_  8ZE_\ )-=CY5W_ ,]4_P"_24>5=_\
M/5/^_24?7,;_ -!;_P#!M3_,/J=#_H&PWW/_ .1.._X03PS_ ,^DW_@QU+_Y
M)H_X03PS_P ^<Q]O[0U+G\[G'YUV/E7?_/5/^_24>5=?\]4_[])_]>CZYC?^
M@M_^#:G^8?4Z'_0-AOQ_^1..T_1M,T7Q!:+8VH@:6PD#$RG(5=ZDD9(XP00<
M].>,5WZNJH!GE0% Y)&  >2.<<Y/?&:Y*8-_;UFIR9#I=Z W8EII<=@!P< G
M'3' !KI0)<_ZY ,'!*@D@_S!]?QKCG4EB6J\ZU2I46\:FCNKVU2O;UVO\CHA
M"G"')3>BOKI?7T^]%I70* 6&1UI3+&,9<#/K5%DE.0+A.G8$')'&?89(P3TY
MQGK$WG*4S<(1QR5QDYZCCOP0/S&#0KM)M6DTFTMDWNEULGM>[%S<BM+X4K*2
MU=EI>7F]&[6W-3S$_O"D,T0ZR*/J0/YUFNT@VIYL>XGNHW<]^@(  '8\8 /:
MF%I"R[YX\'I\OIR<\#H".O [<&B4:CC)4E%U$KQC4;49>G+K:VC\QJI!1]I4
ME:DW:+2;E=.TDUKL]K(U//AQGS%QTR3@?K^OIWI?.C(SO7''?UZ5F8DVC$R$
M#)QM'OP,#J>>/NGKTH42 ;A/&1QE HYP1D8[D'OQQUQ2IRYHM2352'+&K%?#
M"HX\W*KZM-:Q?;S!N6DXI.CKS2=^>]]++16MJ[J]]+&GYT1. ZDYQ@')STZ#
MZU)6/B3S,^<B\G'R#.1R0#CKG.<$D?G5@173#<)5PW(P.,'D8_"J<9)W=E%K
M376_GTV[==!0K4ZC:@Y7CNI+7\D:%4KL'RY3_P!,2!UZY/3'/&/\BF>1=_\
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M_,:E"6L)J:[Q_P"#U\BW1116@RM%CS;G./\ 6*#TZ>6O'Y_K4L7W%SUY/O\
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M )$/]8,=_P __P )?YGU+X4\8P^*-=9H[&>T%K;M"3/-YN"023@$KDGJ0.F
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M3_VKKCXA7_B#PAI_Q=U+XF^$+;Q1X9\.7DVKM!XQU']GO0)E?_A(;%EWQJR
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M/(4RPC9DD= 63/+<#/7)')QS72^7:#@K#D<'A>HXZXY/J>_6A_3V\0U_S1/
MFM]J>:/_ -S/9Z#?T4.$5:^98G6__+F+^^\O7R/\^S_AV5^W-_T;I\1?_!&/
M_DBC_AV5^W-_T;I\1?\ P1C_ .2*_P!!/99_W8?^^5_PHV6?]V'_ +Y7_"E_
MQ/OXB_\ 1$\"?^"LT_\ EY/_ !*CPC_T,L1_X(C_ /)'^?9_P[*_;F_Z-T^(
MO_@C'_R11_P[*_;F_P"C=/B+_P"",?\ R17^@GLL_P"[#_WRO^%&RS_NP_\
M?*_X4?\ $^_B+_T1/ G_ (*S3_Y>'_$J/"/_ $,L1_X(C_\ )'^?9_P[*_;F
M_P"C=/B+_P"",?\ R12-_P $R_VY@K$?L[?$1"%;#MH@"J<'#,?/.%7JQP>
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M1/'<<7A?Q-X@&I?9], EN=*N=.BOIK.QE2^DB5IHM32-'A0Q8'F80*"*]_\
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MM2Y8G#QE&,J]*,I*\4Y).2O:\=-5?3<].\O_ &(?^_?_ ->CR_\ 8A_[X_\
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M6C/A9?2VRR$I0AP_C:D82<8U(I.,U%V4XOE5U)6:=MF?Z0_]M:7_ -!/3_\
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ME/\ ]]-_\51_PDVO?]!*?_OIO_BJ/]2:G_/_ /\ )?\ [87^M,?^@:7W2_\
MDC[<^T6O_/6T_(?XT?:+7_GK:?D/\:^(_P#A)M>_Z"4__?3?_%4?\)-KW_02
MG_[Z;_XJC_4FI_S_ /\ R7_[8/\ 6F/_ $#2^Z7_ ,D?;GVBU_YZVGY#_&CS
M[4\>;:<^@&?PYKXC_P"$FU[_ *"4_P#WTW_Q5(?$VO8/_$RG'_ F_P#BJ/\
M4FI_S_\ _)?_ +8/]:8_] TONE_\D?6\IBE\26BH02-+N=S*0<"221]I&.<@
M]^N1P!D5U(*GYE4<X/;!SG&"1G)^O R.HKYT^$FJ:AJ6L73W]P\S1VI2(LQ;
MY2".<G(()[XYR#QD#Z+52%&2>6.#GD#' '/ [#/J<8S7S>:87^S,;]5YE.W+
M=QTNVF^9+IMJKW9[>7XKZW'FYDXZZIW[:7^_YOJ9LKKYOS1 DDL@WA2\:1JS
M/C'!#C8!W*Y# $+2"8,L1$3*DB(X)8*JHRY!+$Y)']T 9 Z^J7CK$HDPBM$Z
ML9'(51;1J)9E+]MW((ZDGG& #^3'Q9_:._:)USQSXB^'WPQ\&?$#2/'VD?$&
MQTC28KGPKIA^&>I>#;?5HWN_$%UXOU*UO6A:332T2K J(TL9C51)ODKQ<5F%
M'!5J=*=:G2E7<N2-248N=VG:$6[RDV[+K)Z)JS/JLGX;QG$U>K0AC,/@\-AH
MQG)XBI[.F[2:3E)IKECRN4Y:J"<6T[H_7&RDAN6>2*,8:.-@S+OC(902%?@%
MD;*D#^0K0\O_ &(?^_?_ ->N+?7]#\+6EK?>(]6L-'BN9K+2$N+V[CLK%]3U
M"?98V$2SRI!]MO9W6"VBC4RSRD1H#D Y$WQN^$,&H>(M)F^)7@F/5?"5E)J/
MB?3G\2Z0MYH-I"S)-+JL#78>R$+HRRK.$:-E8, 00._E<;1>Z23M9].C3::[
M/JMSQI*49U(3G&I*G4G3YXWM)0DXQW2ULM=+'I?E_P"Q#_W[_P#KT>7_ +$/
M_?O_ .O7.>%O&WA'QQI5GKO@WQ%H_BG1+\.;35]!O[;5--F\L$L%N[222$L"
M"-H8L"""!74T"(?+_P!B'_OW_P#7H\O_ &(?^_?_ ->IJ* (?+_V(?\ OW_]
M>H+B,>5)E(OD7><*0".<  'J<')SZ<5=K/OKE(5D1@[,\8"JB;B2S,HZD#KV
MY]1T(,RG&"O.2BFTDV^K=DMGJ^@U%R=HIM[V79;LDMXU\I,)$,HK\KD -T'/
MI@Y.?3CN)O+_ -B'_OW_ /7K@+WXH_#G0O$5OX,U?QMX9T[Q7-9K<0^'[S6+
M&VU66W2(S&9;.:=)MC1-YB$H Z<J3G%=7:^(=%O;.+4+34K2YL;FVBO;6[@G
MBEM[FTF0-%<6TL;LLT3C&"A8DG !-;.C62C)TJB4_A;A*TK[<KMK?R_R,%7H
M2E*,:M-RA\45)-Q]5T-3R_\ 8A_[]_\ UZ/+_P!B'_OW_P#7JM_:=B5+?:$V
MJJ,Q+ ;5D.(]P)RK.>%1L.QZ*:SQXI\/G5DT#^UK$:Y)91ZBNCFZ@_M,6,DA
MB6Z>R$AN(X/,!4RO&J C[U1)."O).*VNTU^AHIPE\,HOT:9L^7_L0_\ ?O\
M^O1Y?^Q#_P!^_P#Z]<GHGQ#\#^)KS6;#PYXKT#7;SPY>-8>(+;2=5L;Z;1+Q
M%W&WU1()W:S?' \X*"WR@YKH1JMD=V9E3:RJ [(K.S<8C0MO?GY<JI!8$*20
M<5[.I_)+TY7?7;2U_P "?:T_^?D/_ E_F6_+_P!B'_OW_P#7H\O_ &(?^_?_
M ->L2\\5:!I\UA;WNI6UK/JERUEID4TL:2:A>KS]CM4+[I;HIB180 Y1E(&2
M0+,FOZ-$[1R:C9HZ6[7DB/<P*\=HIP;ID:0/]G+?()@I3?E"P8$ ]E523]G-
M+NXO_+H]']V^@>UIK>I#_P "1I>7_L0_]^__ *]'E_[$/_?O_P"O7.>(?&WA
M7PEH]UX@\4:YIWA[1+'/VO5-9NH-/LK<AMBB6XN9(XU:1_DC7=ND;A0364/B
MG\.?M^EZ6?&WAD:GK>FOK&DV!UG3_M6H:5&I>34+6$7!:6SC12[W"9B"#?NV
MX)<:-::O"E4FM=8PE+;5KW4]DFWIIZ"=>BG9U::?9R1W'E_[$/\ W[_^O1Y?
M^Q#_ -\5YWX=^,7PM\7:+?\ B/POX\\,^(- TR<6NH:QI.JVM[86ER5#B":X
M@D=4D*L&VGJ",5W7]IVFW=O^;+*L8*,[[<?,JJY^1EPZ,Q7<C ]Z'2JIV=.:
M?9QDG]S2M\[6ZV!5J+VJP?I)$XMP.=Q+8X)"G!_$?AD\X^II_EGNL1/<LF2?
M<GC^54GUC3HXC-)<QI$HR[EE*H-@D.XJQ!PA!.PL!GDBG-JUBN TRAR%;RLK
MYNQD$GF!-VYXTC82.Z!PB<GH:7LY_P DO_ 7TWZ=/N\]5=^UI?\ /R'_ ($B
MWY?^Q#_W[_\ KT>7_L0_]^__ *]5I=3LH45WN(=LA=8B)8OWKQY\Q(R9 '=
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M/MUC=QO&V8I+:8NLUJR2E7!&3(77'!ST.]/[TW_?0_QI&*L,*TF2?XCTQZ$
MX/./3&<]JSA4J0G&3QLTDTW9ZZ._1)O6W5:I.^A:ITFTG!6>FQYUX.^'7A'P
M!IC:7X*\)^'/"=A+<?;9M/\ #NCVNFV%Q>O!% MP]K;1QR0306\"1*ZRE_E
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MGB(8JLY3OHYW3N[6T7GM^:2/YQO^#B9P_P &O@+EAG_A8GB$L21QC3-)4L<
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M1_PX:_8V'/VSXD\>FOV6?P_XE-'_ !/)X.?]!_%'_B'8;_Y,/^)7O$+OA_\
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M*8<*"QP H))++@  DD\= .OMG@U_:(?^"#/[&I&/MOQ)YX_Y&"R'Z_V32?\
M#A;]C0_\O7Q)/(X;Q!8%3ST8#3<E3T8#D@D4G].3P=M*V/XHYK/E_P",.PR7
M-:7+=\]TN;E3:U2NUJD"^B_X@W7OX5*ZO>M!-JZO;5=+_.Q\(_\ !%CX.:OX
M5^&/CKXQZN;ZTM/B1JECHVB::P9(9K721F37K6,':T%RS&/SP!NVGG K]LS&
M,JJYD3;M63!RP!X?.!][DD@<YS@D&O8_AQ^SW\/OA)X<\%?#;PE:2:5X9\,Z
M ND:=8HB$W)MU*RW<S[>96&=\A/+,><$BO3T^%WAL(@0W:Q[5" N.%  5>1D
MX& #GG!/;!_SPXY\6\MXOXUSSBJ=*4:N:UJTXQY%&5.CSM4*<E!6<HP3E-WN
MW45[.%E_6_!GAYC>%^%L#E=2I%W45)*7?1O=Z-Z6M]EGR@0>ZMGU (Q]<_G^
MF0!1_P!_*^LQ\+O#O9[H@YSDKD<G/!'^>]+_ ,*N\._W[K_QRODJ7&F!C3A#
MV<_<A&/P/HK=4?03X5QJE)0J)03:@E):13T7W'R7_P!_*/\ OY7UI_PJ[P[_
M '[K_P <H_X5=X=_OW7_ (Y6G^NN!_Y]3_\  '_D1_JMC_\ G[_Y,CY+_P"_
ME'_?ROK3_A5WAW^_=?\ CE(?A=X=P?GNNA[I2_UUP/\ S[G_ . /_(?^JV/_
M .?O_DR/DHNO(W/D''/8\=NO<?7(&>:=_P!_*^EY?AQX=&KVUGY=WMFMS,Q!
M&,KG.>",9'/4^AZ&MM?A=X>P"6NE..02F1[$8QG\3]31_KK@5;]W)W[1?_!^
MX;X5Q_\ S]_\F1\F_P#?RC_OY7UI_P *N\._W[K_ ,<H_P"%7>'?[]U_XY3_
M -=<#_SZG_X _P#(G_5;'_\ /W_R9'R7_P!_*/\ OY7UI_PJ[P[_ '[K_P <
MH_X5=X=_OW7_ (Y1_KK@?^?4_P#P!_Y!_JMC_P#G[_Y,CY+_ ._E!Z'[Y^O2
MOK3_ (5=X=_OW7_CE!^%WAW!^>ZZ?[']*7^NN!_Y]3_\ ?\ D/\ U6Q__/W_
M ,F1YE\%U9=9O$=2I^SD,&/.< ]ACMD#.>.I-?3J';C/W=HR/H.F/R^G/:O-
M- \-6'ASQ"HL6)^U:?)(21SE"PW9X&, X&2<\9YQ7I2'=&&;Y6P,@8XRBGOD
MG!/7/3/N3^<\08F.99A]:H)13Y==FM&GOKK^'WGVN6X=87#<J6^^G;7[T^O7
M7H<IXKTXZQI.IZ5"K>=?V4\,;2.\81VAVJT<@^92I&201SGMG'YC?$2?XS^+
M/C#=_"I/BC)\%_"G@_P9I6KC6K:VMI=3\;W,T"O>&RU#4(ROV33]0\ZRO41O
M,:6WE^7IG]6)0'D89E1TP%90-AR,CM_WUG)QTX&*Y'Q/X(\*>+UA7Q/X6\.>
M)%ME0P2:UHNF:P(I!(6VI%>6\S(R\/YB$<M]T,":_*N+N!H\45J-;"9WB<'B
MJ,N6K3I5JD8IQ?-RIP<)J*=MI7TLM#[CA?B>IDF)J1KX*C6I5*,W1JSHX?$>
MSE4A"*JQIXJ-2C[2,(N*52FTN:Z7.C\5_CG\./VD?VO_ -E/0_A];ZKX:U;Q
MG\-_VM/A)K6G>/M4U5?"6F^)?!O@3Q=:ZK>^(K2?9&;B\AL\;8;5X6N+B C?
MGYU_/E?^"<GQ]@^#=I\(M5_9Q^"'C+XI?"_]H%?C+\3_ (XW7Q7\'6VI_MY?
M"NT^*^J^,;[X??$+7)-#F\:Z2WBS1[@6.HZ%KNOZSX?BDD;3;K3Y[%1;U_3O
MX\^"?PZ^*7A^V\'>,/#43^']+NA=:=9:;>W.E16CH C/"VB/ISQ;XU5!$SNB
M]@"#7SPO_!.7]DF -);> -4MIT@^RO+#XR\8F[N4^TFZ=&!ULK+%,S$2P$%9
M49E/<GZKAS*<7DF3X7+,=C:F88G#NNYXNK)SG4C5K2J4TY-M_NX-05W=)>9X
MN98ZAF6/Q6-PU"&&HUJTG"C3BHPAR*,))1245>2E)J*4;RT5M_GK_@EO\ /&
M'[.UM^TKXA^(6F>!O@GH'QK^.]]\1/AI^S=X4\;VOB#0/@CX9D\/6&FR>'K#
MRYK/P_I<>MRVTOB:ZTKPYH^F6=C=:E+&D64P?U6G^(/@6UM8+ZX\7^'(;2YE
MN((+F36+%8IIK1F2YC1S/AG@9&$JCE"#G%?(6N?L#?LS>)]1>_U7P-J\+^>L
ML<&F>*_%EC'#-<,'N+C[%#K(AM2+QI+@7,:B1(F5%PH6DB_8$_9:LM,BTI?
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MS>->OK\R6$+6=MI*2K/+Y9NX7DD::(8E#$L2173_ !A_:"TKX.W_ (7T[6O
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MG^E,#Q#*EX,@X((;"D'!W8Z'V((W=,\X_D TKX^^$?\ A+?B;KNL_P#!3_\
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MX?TOQ1J-CH6J:QLM-/C-W>:5#:RRM'9P!RY(2OO=0WD71./NL%QSQAATX/8
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MRQ7-!-23IVI\MGH[:+WCDH8O+**<Y4ZZA+2*<9.*:=FU'2SO[U]-=SZ$U/\
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MO\-V>LZ8(?'7CJ-/&?B>.2,?;+$7R^3:Z5)B"%UAM5A#+',TDJRLY+;<*OZ
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MD?\ XJE_:.5_]!$?_ __ +87U?,?^@67_@!RF3ZR_F:,GUE_,UU?_"#^(_\
MGV;\C_\ %4?\(/XC_P"?9OR/_P 51_:.5_\ 01'_ ,#_ /M@^KYC_P! LO\
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M_/>'_OZG_P 54 OH26^>/"D@'S4Y(Z'.< $>O3.<XK)_X1G2_P#GQM/RG_\
MCU93Z%HWF2H-,B=HS\Q1)VY9L$#]_P E%*LPQD*P/()-95752C*FN91;<X))
MN::5DNJUOJM?D-1NG+F48P5Y-VLTW;J=6+Z(Y^:(8ZDS1X'Y$D_AFE^VPY^_
M'C'7S4Q[#KWXZXZ\XKD(]&T21VC&GP@A]I+1S@!=SH)C^^R(&9'59,$$J00*
MD&C:&HCW65LGFS/!'YBW +SK(\9C7,WWF9'*] 5!(X-.G4E.+G/#UJ*@G*2G
M\323;Y5_E?8ERA)?NZD')R4$N96YI.R;>^ZV.J-]"%W*T;]>%ECXP/4MZ_\
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M($C"1@/0%Y.!NSM"@;<X//281PY5FEMF"KMVY0 GUX?Z]3G %9/_  C6C_\
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M>K9L[;;UM?\ R%_\51MMO6U_\A?_ !58O_"-:/\ \^5K_P"1O_CU'_"-:/\
M\^5K_P"1O_CU+VE7^2M^/_R87H_\_*7W4S:VVWK:_P#D+_XJC;;>MK_Y"_\
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MW4RE)+%_PD-BRSVL:FR?=&9$$C ;P,#N&QG@DXP.>E;>8&&&EA8L"0XDC64
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M@(/;Y-#T>56C73+,1A]Q*VD!!<=&;]W]W^\3DY/(J%M)T(F.-K2!V<A0B"X
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M_P#QZC_A&=+_ .?&T_*?_P"/50S=^T6__/>'_OZG_P 52&YMQ_RVB/TD0_\
MLWO6'_PC.E_\^-I^4_\ \>H_X1G2_P#GQM/RG_\ CU &O-=P[&VR0DX_BFC0
M#\<GGT&.:=9_ZG(*,"[D%&#KACG[PXR,X-8C^&]+5&/V&#../+,JG/7DM(PQ
MQCIU/XC9L(XXK98XD"(A*A1TR !U[],'W!Z]2 +??\>LWT4GG' =2>OM0;B
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M2Z2OK:SZ[L^YA_P4E_;:."?CWXP4DG WVYQU ZQ #/IC/0G')*_\/)/VVO\
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M_P :/^$VUS_GJ/\ OE?\:Y'!]3^G^%&#ZG]/\*/[)P/_ $#X?_P7$/[5QO\
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M(QD!.6YP1GGF-=^"WQXF^(GQ.U#2+/6K30M;9+ZVUFR\97R:EJ*O=M,NFZ?
M3Y%K!"C! B1#8@ P.:UH\$Y9.<(5N,<CI<]%U7)5;Q@U.$53DW-^^U)R5KI*
M+9SXKQ-SBE%NEP/G=1J7*E*F[OW6_LQZ62?W6N]/U=^VVN?]?%PK.W.,!>"Q
M] ,'.?;%1QZC92#,=U#*,9+(ZL,=<_*2>A%?FM-X1_:CN;&[MG&H)IEHEG"U
MO8^*$75]9C759I9#)-/9S21/!I[QVMP5=?/\LG R%'+^"OA'^UEHO_"(6LOB
MK4--TVS-A+XA$>JV>J:G>RQ6$4+K+//8,$"NA1D4;2^9#UIT^!LOE'$N7&/#
MR=*4_9I5Y6JPBFXM-N_.TE[B6O,K2NF@J>)N;P6%<.",\E[:G3E43I:PG-:J
M-DM(MVM)-][6N?JG-?V<$+7$US#%"BEVED=415 R69F(  ')R1P#0M_9M&TJ
MW,31*N]I$8,@7&[<&7<I7'.02.V<@U^;$_PR_:,U;X:>,-+\67.H>++Q/'@U
MZP\/OKB:'>>*/"EK,)G\./K6F06L^EB^4&(7$1#'=LX JIX3^%?[2>AMHCV6
MI7OA[2[#[#J5CX7;Q-<:W9:#;:MXLN+O4O#FL7MX);C7ET;0)H(U=G2:81[(
MI8VY'G?ZJ8-.<'Q1D?/&I.":JS=.23@H.-FY^_SIN7+R*,9OFE*/LST'X@YH
MI-_ZF9XZ7)"5U37/=Q?.K64;1DK)7YG=:+=_IN;JW4%C*N "2>>,=>U0'4;$
MLT?VJ+>ICRF_Y\2X\L[>"5?< K?=R>37Y7^++W]IC_A:T7@K3_$5]<^*94N+
MJVO]%@EM?!$6FW6B1/&;[3[I+F6UFCNBY:ZN-0N8TER_V=N5K?M/A?\ M*7]
M_87$WB#7=-TN9[>VC,FM6I\3Z7H'_"4W-_=V%ZXL3%<1S:>RPP2;!-%'MC#C
M;N'4N"<+'V+K<59%3C6P_P!8O&K5<DO>]V$)<DIMV]Q25-SL](-1C/B7B=F<
MYUXT^"<^E&CS*[I)7FGI%]%IJ[<UGW5VOTV^UVRJS&9-J(7)YPJ X)/!Z$'/
M?V[U.K*P5E.Y6 8$="."#^N17Y:>"M6^/.G?&SP1X4\7:IXJOQ:VB:EXDFLH
MG'AJ6V@\)6QDBFD6$HSMJ2S2.H?)E;D9QC]0[(2+:6PE(,GD1[R!U;8,GC\/
MP]<U\WG>3+)\13IPS/ 9E2JPYHSP4IRY)7>E1R:C9Q5U:*>J?0^MX2XLGQ1A
MZTZN39CE-:@_?CC8*$)IRY4J>BDY)W<KZ6\][5%%%>,?8C)/N-]*@L_]2?\
MKI)_Z$:GD^XWTJ"S_P!2?^NDG_H1H ;?[?L<^XD#9QAMI+ @H W;<P )[ FO
MSG^/_P"PWI/[1WQ&UWXA>+_B+XJTR<>#_#GA?PKH_AJ]DTW3O#MUHVLZAX@N
M9]6@C)77"^HWL3L)CM5(]FW&%'Z,:@KM9W CA6X<I\L+N8UD(92%+C!4<9S[
M>E<LTVKK*B+X?@V(&96^UA3^\.Z0Y&<>8PR['=DX+9Q7;E6:YEDF.6:95BGA
ML=2I.&&JK6-.522564E9N4:E)>R<4M8N2EI*\?-S3*,#G.&6%Q\*DZ2FIN,)
MJ*=DUJNK5[Q?1I/H?F_XM_85UO7M9C\37/Q/TZYUBYU3Q9?:Q=ZQX4L=4M-0
MN?&7A;P3X=O[W2[-D5=+UA)/"$US%?1@E6O =I  I\_[ -XK?V-9_%26#PC_
M &M8>);/3K_P]97FO1ZW9> O#WP_$\FKLF\QSV'AZW:1>NYB#G%?I-]KU+);
M_A'[3=C&X:M'G _[=><=LYJN;[5CN T*V49((&L+MP#GG_1<<'MTXR*^G_XB
M1Q9RTX8C,L-3AA:C^H>PP5&G*G3<?AJ/E]ZI"4I^S]GRTZ=.I*$8R<G)>&N"
M<@5;2&*A0E34(TXUY)QE&3;<I7LXRBUOJY1N[)I'YKZ?_P $Y-!TNUGM=*\6
M6FD27>D:OH]U<6F@6(;[-J7@GX=^$HE"F/&Z"Z\"W>H2,3AI-5?.. ?1?!O[
M$&E>%/%/AGQC_P )='>ZCH'CV;QE)<#1HK34I;8^"/"7@U-)LKJS-O+%&G_"
M+?;_ /29)K1FO'0VQ(;/W";[6S]WP];D9;_F+VP#%B,X\RS)Y[ALYP3]'&\U
MV0,#X>B*L KJ=8L\/WP0;/! ]#@#IC/%<^,X^XCQV&EA\1F>(KTIU8591C"F
MFY0511O.492Y5&I-<C;CROEMRW-Z/"&04ZDZGU2O)Q3@GB:KJ4I<UDIJ"L[I
MQ3C*]T^M]5^<_B+_ ()^:IXE\:>._%&H?%:-K+Q1:ZW:6VDZ1X+T/P_<W"^(
M+C3[F>#QO>:3:6MOXE@TR.P']F23VRW,4MW>/+/,TH*[.N?L"Z'JLNH10^.)
M](T;4O$6M:T;31].CL);>/6? OA'P;)9V<EH(98F27PJ;MI-Y4"Y:-P<@U^@
M(OM<3[V@1+CA0VLP;<$KG BM1@# SS@<8'6FO?ZPY"_V#;.0>G]L0DCD;L>;
M:,H!]AD]<YJO^(@\6..'A2S>JG@W3>%BZ<53I3HTW2HWBDTU"#E%7NTF[67N
M&:X*X;51U/[)PU2I)\T9J,DHR;;NU+5J]]K;H_-'3?\ @G1X>M/#7AOP=<>/
M+VUCL8/%XO;_ $J&[M9;]M0\/>#]"L)W/VJ06<T%GX7L%O8RKKJ"-+N3#L:[
M+1OV&S:_#[XB>'-5\?6L?B#QGX\\.?$K0]<\'^%[#0-/\(>(O">@Z3X?TB?3
MM#AC^S7-U(FD?:=2N9D,US]JF&0"I'WVEUK08M_PCL*EI%E=O[6LP&<#:)6V
MV0=G" +N!+;5 !VC%2M>:LQS_8EK]X,<ZQ'RPP,Y^R XP-H//'0]J>+\0.+,
M5%1Q>8U9VK>W_=0I4X1K>T53GBK<R4IJ+:NVU&RDDW<AP=PW1J2G5RC#5')6
M]U.+6EKM-23LGI\][*WYK>*/V"M;\?> _B#!XN^,-[<_%WXF>)M \02?$72-
M#L[%- ?PC#'8:=::+8K&196_]FBYC;EB7N6^8G+'MH_V(='@^,7PO^+6C^*W
MTA/A=I7AGP_#8VUC%#=:I:^'K:6TC>]NF1[)YIXV5IE%D)69F/G9.X?>_P!K
MU/(;_A'[4$# )U>,D @ @9M3C( !]ABGF^U4YSH-L<]?^)PG..!G_1N<=O2N
M>IQMQ/6I2PE7&4'@IQJ0="-#EC&G5I4J+ITX6]E&$:5"E3IQ46J:3<;.4G+6
MCPAD>'K*K2HUXM-2=ZVK:;=VUUNVV^MRS9'$<@<E '? :,HS'>QW %F;YL;@
M0?F!#@*K;:N*L<@4[<DC/7W;L.>3R>".<$\9KGC?:N9)%&AVZ@Y&1K*9Z+ZV
MISZ\>_M3A?ZXJX31;8@?Q'64W @ D FVP , GIT)]Z^2YJ%>5:-6-%<\YWC2
MISA+5ZN4F_>G_-*-DY7E&RL>].2C2@J2IM4;4H490E*IRT_=C:6S?*DV[6<C
MH-C+G"\\C(!/'Z]\]>I/?L@#XX!X[ =OP.[TX]>36*FHZ\,_\2.S X/S:U'G
M]+;'/'0?KR9#J.OD<:':$Y_@UF+/O]^U(P._&:QCA\)AX^RA1I:-M.I&<Y>\
MW+63NVM=-=%ILC=3DTKTU%V5U:3LTM4[:/Y&K@@X/4]OF&>YP3CKCD],=,]*
M52V>>QY'R@# [YXY(;.2/RQG%%_XASEM MP,\DZU:G]!: _D:7^T->[Z'9^H
M/]LQY..N?]'()/4\#\N*T7)%/DHT$M^;V<[7^3W5EMT*UZTX/S:>GITO]^Z-
MG)SR=O<<<9XR./KGD]CGFHTA@B8W*)\YR"< 9/0GGGD]QTR1GH:P_M^O-P-"
MM1Z@:S&!S[&V]>O<=!C%*-1U95 ;0[8D8W#^V4^\1R1BVZY/!!_&IBJ,).<4
MHSEI-8>,Z;FKWY9MO6-VVEW;U1,I727[MVO9.$G;3UO^734Z%XXV D9D$F2R
M@\%6YQZ]>>N<Y_*U;_<))!8G+8XP<#(Q[=.@KE#?ZVV"FA6@ 'REM84LO<G)
MMCSDGUZ<=*<NJ:Y$&!T.W)))RNL@CT[6W)]OTZU;5-U(UG.JIQ3CR3;<;2T>
MFUUI:^WYSS2C&\G3MI:,83C.[Z]5ZK]3L:*Y$:MK[<+H=OD<G.L@9],9MB/7
M/X=.Z'4_$!_Y@EKZ\ZTI_'_CV_6K]HFO=3E)_#&S7,^R;5O\B?:JU[2M_A?^
M1U]-;[K<@?*>3T''4^WK7('4O$!&?[$MLCD!=:C#9[8W6I&<9(SP<^E-_M'Q
M&.NA@*<9_P")S;G SSG_ $+D<GY5P">/>JO423=)I]5S)V^Y=+=O6P.O12NZ
MB3[<LKW^2>GGT/@K]N_]AWPO^W'HG@/P1XH\6:UX0L_"&JZQKEM=:'%;7/VN
M6ZM; 8 N8G P(ANP!G) 'R\_G!_Q#U?!YR'7XY_$ LPW,G]FZ%O#-@N#_P 2
MH[<$\@L6R><CD_O>][K$FMZ:%T*VDQ9ZE\S7;MY>)0J@ D#)0+R%X&%X"KC7
M$VNE\C2(59<]-65  >3E?LS%3[;CZ9.:_7N#?'OQBX'R#"9!PAQ]FF5Y-@Z^
M;5Z.$PD*=.E#^TL14Q'+&*I2=USQA7J2DW/EO3Y9-L^+SCPRX3XEQ=3.LSR?
M 9MCL2FI5_KV&4Z5URIR4Z;;:MIHELTKZ'\^H_X-Z?A PS_PO#XAC). -/\
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M%W#.,<]#^0YS5]?AEIY /VV7D')Z\X.[^( ]NPK6GO\ 5SX@LY?["M=Z:;=
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M;W1M/D\&>,=>\-1?8+@R3&VNK;2;^UAG.Z4GS94:7RR(PZH%%>ZG4=;),?\
M8-H<8)SJZ%03T/%J1QW/'L:!?ZNI;.@VBR$DDIK"AF&-H#,+7+$ 8YR0 ,8
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M .6SD@+GN#GK[2A5#[A@@;NI(!!/()SCG(/?&,'VQHK_ %S9@:#8CG)_XG"
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M?[[&XK1XY.?<'KSZ'!]NF3]:=YJ'.<_^/'K^0_+^E87V[7,8_L*QQ_V&$_\
MD;-)]MUO_H V/_@Y3_Y&IQ@HI1C3H))*_N2U[]?SOYL7LD[WJUWV]Z.BZ+X?
MQT-QBC9 4G@\AL8Z=<$\<@>O7'N@$0ZD*0.?F;(X'3)Y'J<=<^M8WV_7?^@%
M8^G_ "&$Z>G_ ![>PI#?:X>NA6)_[C"?_(WL*SGAX2M)4,.I[MN,[-KRBT]N
M[W*@I1NO;57%[)JFVOFX_P##&NSDG(.0.  >O;UY^O ST]:-T:E2Q"_(1SG*
MGWP._3 ZD?A61]NUP?\ ,!L..G_$X3_Y&I#>ZV>N@6!YSSJ\?7_P&K5QE)Q<
MZ>';A%QB^2=TGK97>BOT_$BC1C2J3G[2M*,T[Q<H/7:][=C4!"%F+ #;T)SD
M#DC\>_4\GCK6I$0T:,.A4$<YX/O7+_;=;_Z -C_X.$_^1NG/3I3QJ&O  #0[
M( #  UE  !T 'V;@>U:OE>O)",]FX)).*V7??OIV'1HPH0<(.I*\W*\Y)V3Z
M*R6SZG4T5RW]HZ]_T [+_P '*?\ R-1_:.O?] .R_P#!RG_R-2-#II/N-]*@
ML_\ 4G_KI)_Z$:P/[0UPJ^_1+4+M()36$) /4G-M^1ZYX[UM::TC6JF6(0ON
M.4643 <#G>$0'/7&T>O4XH DO_\ CTF^BC@XZNO<<T\QK\O'*+& >_SO@Y/4
M],\]R3W-,OL&UE]PN/<[UQ^=0/<2*5X7#(IP 2QVMD8YQD]AQD]"!U.E[KKI
M?73LMWV]0C[\W!-<RCSM-V]V[5]?-,T-B^GZG_&O"_&WQO\ AMX \1Z7X4\3
M>-],TOQ#KR&;2M*F,[ZA=0BZEMQ)"L-O+#$IFC:V#7?EQLR?*VX-GUI=1N6W
MKY<1G569;;YA*RK(1SR4#E,'9N!!..XKX%_:+_9T\?\ Q3\>:?XG\(7/AW2;
MA;.RTF3Q'-<ZS!K6AI::G<:IY-]96^I1:/K=E-'=_N;+4=.NA;RF0AR"17SV
M>8_'8:C1GEV!GC*OM9*4)QY(J/*FI*3;OKHTNF]MU\KQ9F6>X')ZU;AS*YYK
MC_:QIJBE90C&2<JCDY)1B]8I[-Z:+5?1UW\?OA);6RWE]X]TBQ#3:_'/%<.!
M/9'PS(BZS]MCV%[6'3S+$;F65?WD31M"_)<[GACXN>!O%LBQ>'?%FC:M,WA[
M2_$\:VDN^WGT'6EG.D:M!($)-E?F"<H2V]8XEW?-N-?(6N?L>ZA?:G\;=>MF
MT*[U3XE>"M!\/64MW(Q\K4[$2+K][<0%39:=!K%M);M.EE;1/-Y:+<-*J1*,
M'X4?L>^/OAWK/CB&P\?+IOAW7] \)Z#X172Q U_H>AZ%;7UQ=Z&L]U!-:MI\
M][J]VUHZ6L4J6HBBB:,1$'YBAQ%QK3Q,O:</4*N#C1Q$N:GB(*I%T[JG[CC?
MWVE)-R?)'=MM,^/J\4^)?MLKI?ZG3J8>6 QL\9*C.'M(UZ--*@E3G)*7M9)S
M3YN6G#=RNF?4<W[4WP<AMO$5_+X^T!++PA>0:7XEV&Y::WU&;>NVT58B;F!Y
MHY8;9XTE#2V]TA8^6<=8OQO^'DFH^#M,B\5:1/>>/[5KCPC'!>AI]:B@BBN;
MNY@@>+ MK>&>W)D<9+2&, LI"_GI;_L4?%JW,E];Z_X1N]4\/7.F+X7@F2_A
ML-7BL=8\4ZF'\6PI=*-3E2W\1)#F(V^V: ^ZUO>&OV+OBIX<^)WP>^(4WQ T
M*ZT_P);Q6VI:!=:49_LUFQ>XO['1KGS2]M UU<RJBD/*8HHD:0K%@\F XFXW
MQ->+K9!1P^#K5E2E7>(BI48.24JLH--M)<R26JY5.]I*WEY;Q;XH5\51IXK@
MZKA<NQ&(A1JXRHU!X:C*24\1-.4Y*$4FGRJZY5-.TTH_9P_:)\)_\)B/!LD.
MIIJ$GC-_ T,R6ADL#JD6BZ;KC2M<JH"!X=4A1224!C. #NJDW[1.@KX[7X?O
MINNQZJWB+3]!>\EM8GLEEOXB\$R3Q#:JR+&9"'RP#D@ =-/3/@EX9M-6\1ZK
M/?ZM=2ZYXL3Q?9K,\$?]E:B-'L](DDTXVT$#H[0643YN6N,/EL;<*N;:?LX^
M!=-U;3]9TS5/$MC>VOB.P\3W[G5&O?[;U"PMEM85U)[];F58"J[VCM'MAYC,
M5PI*CWI8CB2K**A'!M<Z;OBXI\G,DTDZ.[CJFFF[I73;M]C.?%LU"4:.#Y74
MBW?&4U+V?-%-*/L;W<;RWZQ6CNSZ>C4%%)&2<]2?4X_2G[%]/U/^-9T=\HQ'
M_%C RI SR?7\.O\ 7%GSGP" A^4$\D<XR<#.<?\ ZNM?::I7E&4/\<7'TW_K
MMH?>R4H6YH5%?5/D>OXGC?Q@^+_A7X,:&WB?Q?/?I976K:;X?TRSTRTDU*[O
MM4U7>+2-+*%1,6)AE!"R@!4R5YQ4?@'XQ^!_B5X?M?$?AOQ#9SZ?=/?H$N)1
M87D)TRYDL-12[LKC$L3V-_;7,,@SM!4@EB-U<#^TA\%[SXW:5X=\-C5KG1K+
M3/'_ (<\2W\]AJM[I>H-9:5!.LIL;ZUEBDM)%,H"%& 8LQ9<FO#]:_8JBCB\
M1VG@GQ!-HMI??#4^$= $VJ:G<:E8:U-XHU;7M6UJ:_>Z(NGU8ZB?M,TR27,C
MB3;*J;%7XG.<SXLPV*_X2L@6)H1DN2JYQIJK'FE^\C)W33BE)N2U<E9=7\%F
M&:<:8;B.-3!9!"OD5/#1A[6K7A0K5JMIKGI49\TYQ:47SW2;<5%*^OW%'XET
M%H&FAUZPD@$4<PN%O("KQ,Y!=ST1&8^2<%?G4#.215<^,=#C%WYVLZ1&;:7R
M+AQ?P;+&4L61;AI'54)A\LE78,)79!\PVK\"Z?\ L6^.;#2/ &GQ>/GA;3]?
MU#_A/(+6_OG@UOPQJ%U]NMK"Q\ZYE>V?3YXXYH7E\Y29I%*D8K+A_8J\:PW/
MC&*^\>6VI:9XC\5VNIM;W<M]*9=)B\0ZEXBOK?4"UT4:_E?5!I\+VT<,2V5I
M!'Y)978\=;B7B^,ES\*U8R2@G)5:<J;ERIR<963=F[.RY8N\5=V/*K<7>($)
MS4^$5'][+EE+%4.1PYG*#7N)_#RW5K1]Z";EJ_N_6OB[X%T1@ESXCTN6ZDTR
MYU2WTVUN(;C4+BTLIXX+FYMH8Y]TD:22)$Q .&4DD'(&];^+]$NL+#K-C#.;
M:.Y$%U>0&:..XC256OK16CF@6W0C)+KG>"Y(Z?GKJW[&OB.2Z2]M/$>AVVJ6
MFB?$32;?47M+A;S2]$\;>)!K'A^VL)K>:W.-+BBD@E0L9<"(JZJ&W7;C]C_Q
MWJ-SJ<TGCJ"4WNCZC9'5)'O[36M4O-2M=(AMX=1NK:ZBB;3[!;"80QP1PS?O
MB)9FSD\_^MW%E*O"E4X<<5-749U(TYR7,US05I\\9*+7,G'EE[LDY6,8\8^(
M'UB-%\(N2</:-0JT]8J4E>#UY^>,9-6Y;.T97;3/T*A\1Z5>1_:;/6+*X@B9
MH9[B"ZC>RB:,L9I))EN"8Q&!D!I. 59A@@UQ6L?&GP)H'B'PEX4U#7K:?6/&
MEW=6.@0VCBX6[FM!YL[&2+(C2*%XB2V0 06SGCYO@_9E\36/@?XJ>"[#Q'!H
MT'C.;0U\/M8RR;-,DM/#_AVUO]K3&:41:E?Z7?O=?,6,5T=K+)EZQ?"/[+?B
M70O&WA/Q=JFJZ,7T8>.;N;3M/@NI+'2KOQ%;Z9::1'HS:A<7MW##;PZ?OE7[
M2S":67RRL;*J^IBL_P")*<<)/#9#3E*I4DL2I5X1=.FHKE:3B[MNZ2NFM[I'
M?B.)>,U2PE:GPS*DIUI0K^WJ1I<D8K>$'S.;;NOBBTK2VT/K#QI\7O WP_T.
M_P#$GB;Q/IUAI6E;(]0=+@W$Z7C@F#3TBMA)(;JY)*00&'S)"AVL"37#>&/V
MG_A?XJ&COI^MSVO]NQ:Q+96NKVE[877_ !([>&[O8)XYDA,-V]M/'-;P'S&E
MC)=3_"/CFQ_8P^)46H^-=<O_ !U8RZYJFLZ;XGT!OLMY>:+/J6G>)O$.IVEE
MJ^G7ES.L\+:=JEM;W,T)AOXEM88[6[@C15&EJO['?Q7\2> M9AN_BE;/\0KS
MXFVGC?1]36"^&F>'=+6)-/UK0]+%]=WFH+#=6XG$237<D2&0(T3)&BCQZ_$'
M'M?&TOJO#F&5!4ZLI1JXVC"4N5:*\J>DFU:*L[WO9Q/G\5Q7XBUL?36#X:P_
ML_9U9.-;%4J::A&S]YT[1FWRJ"M:5^9IQ?,OJ^S_ &J/A)?>&];\2VVOR_V=
MH4>G7%Y<WD,L3+%K,R1Z=)% KH\D$Y<"%ER6CV2%VSDT/"_[5_PM\5^/[OX?
M6.N7EIKT.HZMX=M8M2L+JRTK5-:T.X"7L6D:I(3%<S'S!$MODM)Y+^6%97)^
M;O&/[#?]I-XFCT?Q&UA:W>G> M+\-1-+J ,-IX.AM(I!J\5O<0VMTUU';>5&
MWDJ8UBC95WF0F3P5^RQ\2H/'&CIXG\2^&Y?A]X9^*_BGXKZ-'IUA>KXJ:[U3
M5]2U73;?4-1O[N\M?L<)U.:"=;6SMY)$@A"RH(R#G3XCXZ6-P^&Q&08>E&IB
M(4IU:=:%2$(R;O4E)1Y8QBM;N^T6TU+2</Q9XC+,,)AL5PWAXTZF)A1J3IXB
M%6"A*3YIN48VA!);R;LU%ZJ=H_=5G\3/"]_=:M;C4H[9M$U>71KL7TZ62R7D
M-I9WLB6XNG)N%2&]@+-'CAN>"#7:1SR7,"2Q2$AV41D%)(KB(,6$J.HP1-&\
M;!D.W&W: 22?S^US]D[Q-KOB_6=:U7Q/'?Z7J>I>/M3LK&:XOOW4WB/PYX9T
MK1)E*7*&.:TGT:Z9"FU4+C !8@?9OPU\/ZEX2\!>"O#NL77VF[T/PMX<T:XG
MWR2//J-AIL%E-)*\K.S&4PAW8D,SEF!PP ^SR/%YO6Q559G0A2BHR=/EJ1JJ
M3O*RY815DU9WZ;ZK?[WA_-,YQ>-JT\RR>%&*]Z,E4A53UDG>T5;2TDM[)VOT
M\J^-O[0/PU_9\;P_J_Q%U==*BU274K&R!A9BUQ'#:3,CL"0"1*''RG[V,\8K
MP\?\%,/V8.WBP 8/'[T G&>I7 ''0J1ZGGCY)_X+&VP3P/\ "=U=FGD\5:^&
M,C!T5EL=+5-KONW87CYB^",# 49_G\59=IR^YE)1G+*"[\ MQ@<G)R%"]ATK
M^/O''Z2'%7AMQI/AK(\JP-7!TG&52>(JJG47,HN2IP?Q1YK\K23:L[(_SM^D
M;],KCOP:\6^)N!L@P'!M;+LLPN6U^;&TJE*JO[3PE/$8=:**JSY)J55)>X[<
M[E=V_JV'_!2C]EA@#+XN <\-\DK].G(50W& <CIUR>CO^'D_[*G_ $-P_P"_
M,P]NF<?IBOY1G62-BA() Y(Y!W 'KCJ#QZ CM@YC_>?YVU^23^F?QTIR4<'P
M?"*E+EC7=7VRC=J*JM1?[U+2IJUS7U>Y_.M/]I'XK*$.;A/@"I+E5ZDJ&;MU
M'UFW#&1@W)ZODBHZZ)+0_J]_X>3_ +*G_0WCZ^3/_0BD_P"'DW[*?7_A+ESZ
M^3/_ /%5_*'^\_SMH_>?YVU/_$Y_'?\ T"\$_P#@5;_Y$O\ XJ2>*O\ T2'A
M]_X(SG_YM/ZO/^'DW[*G_0X?^09O\:3_ (>3?LJ_]#>/^_4WY].U?RB?O/\
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M^9[S_P )EH__ #T'_?4?_P 31_PF6C_\]!_WU'_\37@V[_=_[Z_^M1N_W?\
MOK_ZU'^N>/\ Y*7_ ('+_P"3#_B(^:]L-_X&O\SWG_A,M'_YZ#_OJ/\ ^)H_
MX3+1_P#GH/P://X87.?IS7@V[_=_[Z_^M1N_W3[;LY]NG>C_ %SQ_P#)2_\
M Y?_ "8?\1'S7MAO_ U_F>]V6J6^IZQ;&WGWB.T:.3:PQO(;:3MX[C(QWZDX
M(ZQ%8_*<@X.1N)&<*>Q.<DYXR3@8/>O%OAXH_M.;J/-PY(/S+WVC/(5N^0<8
M.,\U[6#DD\;MO XVE>""3U)SV]B".U?=Y-F-7,LK^M5E&,G%KW-=%;9+7KW_
M #/T_A?-L1F^5K%8KD4FVK0?,[+1V2ULK]TSYB_:&_:=\$?LZR^$H_&#SI)X
MOU&ZTW3CYUO!;.]K:QSR,SS3HWFJ) J)MPQP>_/C7AO_ (*!_"GQ1XFTKPGH
MMEKT^NZO'?3PZ<IL3J7D6!GBGFAT\7'GWX,UM,4AA:-V"H0WS 'P+_@JO\"?
M&GQCT/X4:CX7\/\ A?5;;PQKVKW6LW?B/0)M8@T\SV,$>G3QM92V]\LK7,>Q
MLRM"%"YBRK%OBS]DGX)?%3Q?^U#\,?BWK7@/X=Z98Z(+FRUJZT?P?<6=[HEC
MI6IW8NT2\O97ALVOK4?:0(X#=O%.I%P,J!XM?,\QIXZC1I1_<RE%7O:\'9)R
M5NVZ\FG?0_2,!PWD>,RBIF6.SAT<7"A*MAL/"\]5&3A3G:2Y&W%)<R=KJ]S]
M3_AM_P %"O@E\2]7\!^&O"$/CS5/$WQ+\*>'_&W@ZSO/#L>EIJ_AS5?$-UX8
MN9OM<EY)$NH:#?Z?=)XOTP0BYT::WN#(T<:HB_8/@7QYI_C_ $BZUK15U>WL
M=/US7-#G?6+86$AOM!O[C3+PM&6*SZ?)<VLDMM>12PK+;O$ZD@C/\]'C7]GS
M]ISX'_M'7OBSX/\ PBN?%/A;]GK]HSQ-XB^%MS%:6ZKXC^%G[92F^^)O@[38
M%58H[/X:>)/%'B#7X9S&;BT.V**95B5 W2%_:*@U_P ":3X.NOBWX+T=_!/B
M."7P1\0K/QAK6@>,_'/@GQQK=OJ&C_$O5=-URQ;2?^$VL+%(_#NI>$?^$>BM
M;:YLYKU+O$A?["7,^5S5I.$&U>^KBCY&G*<HOVE15)*<XJ:MK",K0O:RYN7X
MENGH]4?OAX ^//@3XD:#XR\1:)?ZE8:1X$\8^+_!?BF_UK3IM,31]6\#:K=Z
M+KHDCDGFDDM&OK"X-I=A3'-"4D&58"O5XM0AO[2"ZLKP2VU_;P7=I- Q60V%
MPBLE^@E\SS$5#YH'E8*'D8P:_F/NQ\6O#7P4U/XD^%O!_P ;?"'COXB_'KXR
M:1\1?#,-UXB\26MGX8\1VTQLHFT>_GFLI["&2;-GKJPK/'J(DGF:=/D&1X^\
M4_&[X?\ P$\3?'#1_$7[0&@^)-(^.L?A<:KJLWB&6#2/A_J?AO3+*[DDT:XN
MFTBP\/V5VUPL5REBIA9MWF@C<)-#^HF;4;>"]BLFNHS=7222Z?9-<H+F^1(P
MTSPPAO-:"W4-*9%&"@)/%3M<.Y+P!F1R8X727[1 X R)E$;([N6!C>)9<Q]2
MIK^4CQIXA\2^-/CYH_Q+\&']HA?%^D^#=%M]?^$5K?\ Q#MX?AI#_9%E8W\-
MO=?\)/<V]Y<^(K17U2Q+.W%VF0W%?6'B/PC\2?$/[4'Q"TSPWJO[1-E^SS=?
M!/Q?XU^"NE66M^+=,BT?XD:5X6\_62]^FJC5+N];7X[J?1M,U.[N;(M(D;6L
MB_+0!_0K:)OA#.TC'?( YE)+IO.QCM6,+E<?)MRGW26(R7S(%CE(9P4CW*=[
M=?FQW]AQWY!S7CG[-6M^)O$O[/OP8U_QI#J5OXOU?X:>#K_Q/;:O"\&J6^O7
M&AV4FJV]_%(6D6ZAO6FCFWLSEU+,Q8FO5M3N+B /Y8B\IX&!+;FD\S+;=L89
M=RX)S\P]<C%3.=.G%SJU*=*"5W.I)0BO5M/5]%;5AHE)RE&$8QE.4IRY8I15
MWK9ZVV5KLNP(KQH26),<;$[VSEMQ;OWP#4WE)_>?_OXW^-?$OQ$_;#L?AW\3
M8OAJ?!VI:S/Y>B@WE@SM)G5\)!_H@1B(H7):YGDD2.*(!F/8Z.G?MN?".?P[
MI.O:O-JFB-JMU8V T^_TQTNK.^O88KA!=(LSL+)89$E-^ (WB(<)@XKYFMQI
MPS0KU,/5S;#QJTI2A47ON,7%V;<^3ELGI=7UOI;4^-7B!P@J^+PU;.L-A:N"
M=18A8Q5,-&/LM)N,YTY1J)/3W+MVVMJ?9/E)_>?T^^W7TZT>4G]Y_P#OMNW7
MO7R#<_ML_!*SLKRZFU?5 -/\1KX9GC&B71NI]2\P!I=.L0_FW6F*C!WU ,L:
M(=YC.<4[QY^UMH7@C5?$EE_PB/B74K'PWX1@\9/JPLC:6&JV-S<FU^QZ-*TL
MLEW>Q2*?,A:&(+P-QR,]4^*.'H4/K,LXP'L?=O)5U)KFORWC&+:ORO[K=N;2
MKQ]P91H?69\2Y2Z5XWE#$NI;GYN6ZA0;5^5K7L]G9/Z\\E/5_P#OMO\ &CR4
M]7_[[;_&OC/7OVP=(M-+O=2\,^%M0\1MHUA+>Z[:3R#2)M*EBU)],FTV0SF<
M7.JQ31N8K"("6[0!H2H9:NR?ME_#:*'QPI-[+J?@+PW%XFUG28K207364Q,(
M6V,KI&YMK\/I]PX<%+B)_P!V,8K#_7#AO_H:X;[Y:I;M>YJDM[=FM]"_]>.%
M/^AW@N_QRU6[:]RS6^S\K7T/K_RD]7_[[;_&CRD]7_[[;_&OBG3_ -M/PO81
MZE:?$#PKK_A/Q#I)?[7H=I#_ &[*;>/2X=7-\)H6ME2 V<R2.A5S'\R%GQN/
M:^(?VMOA1X>NK"UGUH7_ -L>TB:YTNVENH;!KR\;3Q/JRAU.FVBWB/ 9Y&DV
MR(Q9<#%:2XKX<C0EB99UET:49<LKU[3C*_+RRIN"DFFFI+5QM=V6H1XXX4E1
MJXA9W@E2H3=.HY5'%QFI.+7)*"D_>35TGLV[+4^H?*3^\_\ W\;_ !H\I/[S
M_P#?;?XU\BWG[9?PNLU25CJ<MG')?&\NS9^4?[/MK!=0MM9TNW:9Y-3TV_BD
M003(T!!QN!Q@V[?]L/X4S2Z7;F[U!KB_U2'2+F./3)F_L>]FU%M(CAU4></L
MCRZE&UI"A#YF4J6'6LWQAPVI0@LWP<G-1<7";E!\RNO>4+)K[2>JU[7'#CCA
M&I*$(<098ZD[<M-8A<^MK7CR-JZ=UOI=Z)-KZO\ )7U?_OMO\:/)7U?_ +[;
M_&L*WU>XNWMVBCA6":3&YV;S/+/W3M!^5R",!N.YP.:Z*OHH5*56,9TJM*M"
M234J4U-)/5)V2LVFFEKIKIL?4J4)QA.G4I583BI1E2FIJSLU=I*S:::3UMKH
M1>2OJ_\ WVW^-'DKZO\ ]]M_C4M%6,B\E?5_^^V_QH\E?5_^^V_QJ6B@"O)"
MFQN7Z?WV_F#GCM3;0DP\DMAW +')P#@#)Y/ [U/)]QOI4%G_ *D_]=)/_0C0
M V_(%I,2,X"_GO4#^=4)W58W;:V(X@N ><%"<J>QX^N>AR:T+X,;64+MR0N-
M^=OWUZX!_E59HF=6&8LNJ@C(QC&&QP,=3@Y]#U-9UHN=&4()*M*ZA4Z1O%6N
M^BNOQ\R&[NK"$90K3H-0Q&T(WDTH-_S)^_:VTMS\HO&'[2GQ9T?QEXGURR\3
MZ-96_A3XDQ>!;+X-2Z9#/JGB?2Y+6RFMM52[,PU-+K4+6XEO(;Q-UM'Y+*T3
M2<CNM9_;HBT/P[H?B2Z\!7\-OKGB'Q'I^GVW]M67VK[#X4\2-X7N=?N=^G$J
MMW>+*$LI09$6!F:5MRD?:]_\'/ %_P"(O^$NN?!WA6Z\4JUOM\0S:)H\NL*+
M5)([>0:D]DU\)H89#"LWVC>J*H5E4!1!<?!GP#?VT=GJ/@WPS<VEJUV+*.;2
MM.F:TBNY8KZ\0,]JTDC7NIB>_N79MSW$K2R,SL:_/,1DG'[Q%:IA>(L'"A-W
MITIQYN6S;NU-2M>,G'E@U&+BI):L_)I\*\?0>8U*?%OL*6(J*6%H8:#J5+JM
M.4G44_@3IR45&#Y%*"DEK=?$NL_M(?$BP^&/B+6EU/3X-=N?B_JG@O1-4>*V
M6VTO2I-1O[>R\^*>-XY)Q':QH6N697\S<@2/;&*%[^U7KL'P3\Z^U!(_BQ;1
M2)<W\>D3MI48L/%;Z*0)K2!+(R+';R*XC 5@Z2+M4 5]G^-?@#X!\=:-8^'M
M:T>PBT6S\5:=XQ-AIEO#81WFK:=)<2I_:,=NL<%^EQ+<NTHN(I%*HBNI  '8
MVWP^\/)I4WA_^P]$70I@"VG"RMQ:;C*]U(K6B1K;[GNI&FDD2-5=B,J2*O#Y
M/X@TG5G5XAR]P>%G15TW^]G*\9+K%Z)7L[+1)ZG13X:X]C.DX\9XRDUE]>G*
MI4I-P5>7*XO6=HU)+W8NTFDG&*6Y\07'[<%@-7\:^'CX4O1<>&Y+2*QOGU2R
M33+VYU#6]5TB9)K];-CIR17.E22-+(CJ4N41<&-F9^L?M>^(/"/C#78=8\%Z
M*F@V'P^TCQ%;P6_BF"]N+S6]4UG7--AL+2_%J+2>W#Z8QN+E+5"@>,-NR*^R
M8?@U\.(1?L/!'@\R:LFS5MWA_23'J86:>=!=*UJQF*S74\ZL[$I--*XPQ%1R
M?!7X97$4,%SX(\+2PVVFKI-O$VCZ;(8[$32SM KM;$K&99'G4?P2R.<DLS'*
M.5^(BP'L:?$674L1SRE"<,,JO(VY.,E2<4JCCS-*%DG97VN^&7#/B@L%RT?$
M#V>)]HY1=7"J=)>])Q=:FX^_3CSN\79.T$TTKGQA'^WQ'J"^'O[+^%%WJ!U:
MSTZ64MXILX!9ZK?:IXCTF73PO]EL7BM[CPU=DW>5CD$D0"#!+:T'[=_AZYUO
MPKHL/@.^ED\2Z)+JAEBUBWW:;?)ID6H_V6T#66;F3?(+43J\:&12VS!"U]B6
M?PC^'E@4%MX'\)QBWCM8;<IHNF(R0V\MU<J@VVV(V6ZOK^;S%P2]Q)DDL6(/
MA%\.H[VWU&'P%X2COK=&@M[I-&TM9+.#RE@ AQ:CEHE53@J5 SN)ZXTLG\44
MDY<9X+2VDLCIJZ2V22NN9WN[K>ZL7'AWQ?=&*_XB/E+J*U_^$2ET5VKI*R?V
MFG?72S5CX7MO^"@^F/H.GZP_P[UF/4;G4[K3K[1GU>P6;3&L[33+V59+I;$P
M3WIBU.)(]/39(\D;)YN>GZ)>'==BU_1--UB*VGMEU*PM-02&Z54NH4N[:*Y6
M*XB&1%,@DVRJ6;8X90S8KA(?@;\.8K6.P;P7X3:T34'U3R#HFEFW.H,Y(NWC
M-KNFN6184ED:0LPAC'"H OJEI:06D*0IY*;(UCVQ*(XE"H%PD:KA%& $0$[0
M "< "OI.'<#Q)A5+_6/,J.8RY8J/L$[<RO=M:773IWLMG]/POEG&V7O_ (R7
M/,)FRM!+V$7&UKN;UBOBV6S^THQ6C^8?VDOC#JOPA\&77B31M'M]6U.?4;/3
MHK:ZCEN('CGMIY9)'AA7>Q'D! NX89@S9V@5\0:C^T5\6-4U/PMXKLY=;M=.
MUC5?@]K,_ABUL]T=O:7^C:Q<ZYHEJQM0T@N)XH%DW'Y-ZF0, ,_K7J&E:5J2
M/;ZG9V>IP)/'/%;W5O!/''(J,H8>;$W7>Q^<'&X@<51D\.:)']F$.D:8L-MY
M36VVSLU>QEM$$=B]MFW;YE3S$).?*4D( "<<N=\/Y_CZ\ZF"XIS# X>=1SA0
MH1?)1@W)QAS*2DO9J7*HWY?=2?NH\_BCA3B'B+,85LOXPS#*Z-*?,L!04THQ
M3E91M*+ERQ=E[W))*-URI-?#?@W]JOQAKEKKO]H^"-=U'[-HNAZK!>^#],-X
M^D7&N/=P2:%JBRB(R:IH @C-\T159 Z[(HQQ7SCIOQ[_ &D&'ANXNM)OK=9-
M%^.,EI>O+#/-K5SH6O"WT.^NM&_LXOIDUG92,R0RW-RSF$A&8-7Z_P!IH6E6
M*SK86-A8)<RM=W']G6\%B+FZ>1FEFF2&)1++)A?,ED+;L' !!-1+X;TR%D:W
MLM,C,+7<D+FV@,L37\AGOE23R\AKF0Y=Q@,"0ZL1FO*Q/!O$.-P&$PJXUS6-
M3#SJ2J8F$;.MS5'.*YTXR?(GR+F_E2M:]N+,>!N),QPF$PSXWS:A4PK?M*L4
MHRG:5U[RFF[*R7-U5MKGYE>"[Y_&_P (/B+%H/Q_\?\ BW5[715\1WLUM+%%
MJ&@^)X=+>2XL+>2XT:)X;1[N!A%IPWFWQM9VXS]:_LL:7XAM?@CX%NO$WB#Q
M#XDU;7?#^AZ_J.H>)YDFOX[K6=(L[RYM4>**$JD%S,Z(I3'!7 ^7'O-MX7TF
MS$Z6.E:3:1W8G-Y!:VMI:PWAO?EN$NHK:WA6YEC'^KN90S.7?.,G.Q9:;#8V
M=I8VT45O;6<$=M;VT6V.*."%!';*H50,I&JKC' P!D"OH\LR?&X#&X'$8S-9
MX]X7"/#-XIU/:.]5U/:0YY2;6_O/[3?D?0Y+PWC\OS/!YAC,_P SQGU/+98+
MV*=6=*K-XAUO:-5*TE*5KQU5[-:[6@-LN5<+N*QE01GEVP&<@DJ#A<*!TR>>
M>+GDEO*8SE1$R,$VCJFXH&)!8[0Q4XP6(.>]2A9"^UQ&HY^X26Q\P)_#&0.>
M.6]*D;8O#%R!C Q@G)QUZGCKD]P>>:^IDZ\ZTIQG3E3<(QC'X]I-N3VC=IVT
M2:5E=)*WV,<16FW*/UBJYR?[K%4E%4XK6]-7>CO9O3H[D*PRY)$J,K'S/F1\
M[U[C#!0!SA54$=^<TU+<H"GF)LD)8J0Q;+'=D$DXS*7<^Q &*NEL[=K*,DX#
M?+C&<YZ\?7'6HO,.2-T?!(P><8ZXR,X[@=A[YHOB7LZ4=M>771[6?HC6,I24
MG!4/:0:4K))Q;NFGI=/3]+,KFVEDBVF=GRRR>80P;>G&%V%=JC@!<8X(.0>&
MI:E;@SN0'>%8)20^UHDD>2-%4L57#2O\P7/11E5 %]7R.J\8.%.1@Y],_7..
MV*<06P5*[L#AB,8[Y&/?BIYZFJG"E+1W:BN;56=DU;;;33\U[22=G"ES-V4N
M6*<96:3O:^F^B3[6:90^RGS6D9XV#?* 4(*1H%\E$ /'EN9&R -P?'&*)[=9
M0V63Y6,A !^^"0K9SCY5R!Z>_ %SRYC_ ,\L>N[G^7K[_P"%!CD(/$><$9W=
ML<#G.1R,_3IG),U)+#Q]I1I*4]/@M)J[5[K1Z7;OZ^A,%B*4I5(U:3;3LDKM
M/7MJWKL[K[S\1O\ @L)9:CJ'@#X0V^GZ=?:A)#XB\0R$6-K+=LJ-:Z:1(5B4
ME4R0N2"201@\X_ L>%O$Q4_\4_K:D,N4.DWV_)'?$)^Z2%//7/!&<?VPZWH.
MG:_K%G!K.FZ9J4"P7,MK#=VD%VEM(L<$,WD),DBH)&CRQ&&+*-O>K"?#KP7)
M^\?PMX>C,0$2"/1M. =!C:\@:V)\PGJ.F0.M?R3XK?1G?B;QGB.*)<04,.YV
M]EA8J<VFDFH/W8JUW9M7M\6VW^?/CY]"JOXZ>(^<<<3XZHY76S'!<,8?ZJ\F
M4I-Y?@:5'$J4E&*<H--3B[N$KPE*:29_$N/#7BE1C^P-:'/&=,O <8SG)A)Y
MQP.H'4]:=_PCOBG_ * .L?\ @LN__D>O[<8_AQX"D0,WA#PTY/\ %+HFF%R
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M8^-_Z.9D7_B(8G_Y<?Q%?\([XI_Z .L?^"R[_P#D>C_A'?%/_0!UC_P67?\
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MW&4?AEX%N D<W@OPA+ MU%=R(-$L0C7-DD<>FW!5XCNN[6&&!!<,2^$4+M
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MK+16E=66^G46BDR/4?F*,CU'YBM#46BDR/4?F*,CU'YB@!LGW&^E06?^I/\
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MBZZ-<L+2/4M6TJQUE=/L=6UB77K?3M2LQ.K>;:H^E))*'WG=)MW\@MP7A/\
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M_;%?S3WUVMT_X-ST;;%_??\ 7_&C;%_??]?\:\Y_X6)!_P ^<7Y-_P#%4?\
M"Q(/^?.+\F_^*I?V]D'_ $&R_'_(7^MG#'_0;'[I'HVV+^^_Z_XT;8O[[_K_
M (UYS_PL2#_GSB_)O_BJ/^%B0?\ /G%^3?\ Q5']O9!_T&R_'_(/];.&/^@V
M/W2/1ML7]]_U_P :-L7]Y_U_QKSG_A8D'_/G%^3?_%4?\+$@_P"?.+_OEO\
MXH4_[>R#_H-E^/\ D'^MG#'_ $&Q^Z1TLZ@^(M/)DQYFEW87))+;Y9&'/?(Y
M&>1W&:W62+>5#2ERQ/((!R<DKDC"\Y !&!G(!KB=)UNWUW6;>ZB&U+2U:$#&
M"=Y8D 'D\L>,8%/\>_$3PC\,O#6I^,/&FL66@>&],A,]WJ=]GR8%'+/(Q(5
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MHA:P6]P+IE@E:*1F66,2;8W5DDF8; P(.T]0+KNOO7^9Z"+:,C(\_!Y'S?\
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M<O\ >7\Q2%T!P64' ."P!P>AQGH>U%UW7WK_ # I?94_Z;_]]?\ V='V5/\
MIO\ ]]?_ &=7=Z?WU_[Z'^-&Y?[R_F/\:8;[%+[*G_3?_OK_ .SH^RI_TW_[
MZ_\ LZN[T_OKUQ]X=3T'7K[=:7<O]Y?S% ;;Z>NGYE'[*G_3?_OK_P"SH^RI
M_P!-_P#OK_[.KNY?[R_F/\:<"#R#D>HH H?94_Z;_P#?7_V='V5/^F__ 'U_
M]G5^B@#.:VC"DGS\8]<_G\WKS4]FJ+"0F_;O;[_7/&1U/ / J>3[C?2H+/\
MU)_ZZ2?^A&@!+[_CTF^B_P#H:U,?Z0_^AFH;[_CTF^B_^AK4Q_I#_P"AF@"6
MLF?N/-P/F3 XSG<. .^,>A/.2.<ZU9$ZEPQP"%D .?\ >..V,$''IZG/%$)-
M5J</LS512=EI:*:W\W_72HQC.2A.W+-23O;;E=]_77KV/S2_:S^!OCOQW\1=
M$U_P-X:M[[5;;1;'2]-\2G5;!)-"O(M5-[=R:AHVL:3K%G)I-Q:O'"^I:/)I
M.M+(LD/VAXHX\<]XH_9.\1ZEXE^,6LV.D6=U9^*_AU::=H.C)<M'HVF>,];N
M+F/QI-I"N,Z2/$5I%I;7\J;S=?9(&E8LSU](_M!_%'QIX<\;>"_AOX'O_#7A
MB^\7:=XMUF[\7>*+)[_3]/MO#-KHTL=I8VZ:AIL,NI7[ZBZ-Y[3_ &>"'S5B
MF,I,'C_P_P#VTWU#PU?2>+?#$#7WACPCJ_B'Q7K.A76_PVXL?%VM>#M).G1W
M7G32QZ[<Z!-<I$99ULW:2))IPIFE_',YR_@V6:YG2S;%5\+.K.I5J5*$;U%.
M$+.,.5.<M))S3Y8^[%N]G;\"SG)N!5Q'B8YMBJV&JU,9[64Z$4Y.K"G7BH1Y
M(RJ.+4U*;?+%<L/B>L>)^!O[//Q_^%/B/XBP6^I:!::2_@3X:^$_ .MZQ9W6
MK,F@^'1J\FIZ#=6=G?:;*T^E7.JR0V5XUR/,M/(WQMLKS:W_ &>/C/X6LOB;
M>2?"7PQXQU"[M8-%M[&&YTN]B\;7UWXM\4ZU=>*]3TG5-(>W2[TC2M<TZUT^
MUO9M0E\VVV_:5"5])>%OVLM6\?:[IC^']*L+?0;GPA\0[Z^L;Q)WNK7Q3X0N
MFL%L975E9[:%X$N=T3*K)<J&#*H \1L?V]/%$/CKX6:/>3>")=%US1=!3Q[-
M/8ZM<WMOXI\8F[&F'3KZTECTNPL-,6T O8KJ,3M]LA F0AF;P,:O#_#Y?@*,
M,YSVIAGB(TU!PE*,^9M22<E:/QPDY73:5IM\EE\AB8>&>&RC(J,L_P"(J>#<
M\\IQGAH5*E91J5H^T="Z3C5A*I3DG=2<>95&^3EC8\$?LU?$K0_B5\+M0_X0
MV"#0]*USPMK8\5ZG?VCZOX1T[0[.\BUKP:1:V,,D\.NW5TFIP6\4D>GVM_/?
MVL:K:0VRU^LELJQQQHSAWCBAC;!*X*@*20>0<]>F,XZ=?SC_ &>OVC?C5\2_
MBK+INIZ3H^I> SJWC?2KFXLO#&J^'CX-/AG7+K0]/LI-3N]8U6V\0R:PE@US
M&8+>T**3\ZK\H_295RBX2+?($=\@8RW)![X]B., DX%?;\!KA[!Y7BJV4U<Y
M="IB9<ZJTZD?>5EHHN*<5>TGT;?9H_6?"S <+4\FQ=?AZ>;YA0J8B7[S.Z3I
MU7)))Z54U:-VKI-J5U=<ILT445^EGZB>1_$#Q?H7@UK.\U:SBODU/7]*T:+,
M\<;V=Y?QR[;HBZ)BV0PP(Y$0W8.0-V<\@?C+\(=3,UR_BCPMJ$OA8B\DN6$<
MUSI0>>:PDNK:62,F.1IX)8#);_N]\14Y(Q5WXS?"O3_BW9Z;HM[J$^E_V!XF
MT?Q-'<"VCG29].@NH?LY+@@(XN<MD8#*"5/!'S7<_L0^'8;'[-;^)M0@NDT.
MTTS3[F&VT^.VM[W3O$FL^(XM5U1?)4ZE:R#6GM;C3;MY["41(\D).*^*SRKQ
MKA*]LGR?):^"J/FG.M52JRBWI.:3LIN#4II\W,VU:+NU\#Q#6X[P6:TY</Y-
MD^(P=3#\U2K6JJ%:7-=J<U&5U-Q:G+FOS:I<K;M[9;_%[X,S^,F\.&?1HI8+
M#1O$=OKEU"HM+S4=:O=0T73#;7>U5.H22:1<+(V%D=50#IBJOCCX^?!SP'I$
MNIW6J:'JJQ:B=%_LZP1+C4(;N^U>?3KZ-FVN\</]H"X%PI(RP8LN0#7F.K?L
MF67B(W5[/XRU&35HK'PW!9O:Z9H>GZ?;3>%M;UC6+&^CTZRM(K8I))J\R%C'
MF5(@Q))K@O\ A@FR%E=1?\)YJ5S_ &]J=UJ'BBYFLM.WZPU]XDU/Q7_Q*,6Q
M?2YDFU3[,;JU*3;($&1C:/*Q^.XWHTJ3RGA?(\36GRJM55:FE;9JREHXN\7K
M+E5V[GR&.S;Q.HY;B7E/"N28BO*I-5:BK4XQY.=IJRDH\T=8ZN7+&[=VT?3&
MJ_$GX30>%?%&MZ?>^'M7A\ Z7?:IJ&E6-E;WUYIR:8\L4L@M6&[SIX[4642[
M5$DUMC.4 'E5C^U_\']2\*WOBJR@NY=)L?A]H_Q3D$MA;37 M=:NK[3;33EL
MECS'X@LI[$P/#O#Q!T4N<G$7@;]C?0_!FB?$>T@\3:K+/X\T>ZT:342J37^G
MV5WK>H:YMO'<%M0N4;57A6:X+R",;0P48KAKC_@G]X 75?$$]KXN\066@>*;
M/P;9^*O#=G?-IMGJD7A&-H3_ &9=6Q@DT./4KC$U_%I\D"SWT,UW,LEQ/)*_
M#F-;Q):PV(R_),BP<70FL=2=:$7]:52:C44V]4J4H1:]YVBE%)O3#&UO%>MA
M,JQ6#R3(<&O[/E3Q]&5:,7'%*O4Y)PDW9Q]A*":2DFHKE7-*QU^I_M;^!T\+
M_#G6--\ :UKTOQ3CU.&VT:.+2-.N=.&BF"/6HM;:^N53S8+N=D^Q;Y'E8,CJ
MK@L?2++XQ_#U_"OCW6'\/BWM? "M:ZYH4NGP6MY<RRZ'IFL)90VT>;)A$-16
MW56+Q-M&TD#YO,_"?[$/P\\/>(=+N)=2N_$WA7PWK?B7Q'X?\,^(!!X@MM*U
M'Q9!IL=]LU'4S>7%V]M>V$VI8N-[O/J#.SEUS6QK?[+.N:CX@^(K6'Q2O[/P
MA\0VFN[[PL^E:+(;&5-#TG0X)+6^-M]I4P_V0)?*!V*9&0CC-=.&EQ_"@J^+
MR[(\1*K35-0C6I2<*D:5^>^RC*HXO=R4;JUSIP\/$B%"-?&99DE>5:'LXTX5
MJ+Y:T:-^=-KEY)57%[\RA>-D]3'\'_M2?#O5;*[N=9\!ZUX7U70M(T35;+2=
M4TO35U>ZT?5_MDFCG15M@$>.$6]S*L<1'EASN =F-3^#?VL_@AXVM=..D:6P
ML_$.D>--7N$O;&SBE*>#;QEU6VUJ(QOLGO;AS<6*R B265VR"Q)H^'/V-GTR
M>QUKQ9\1-9\5^(=.T?2M%TF_DLM+TV+3?#NF6]XD%I;V-M:K!->1RZC(3<2*
M925'S$DFN/O/^"=WA=)H)M/\9:QI+ZEX'D\">((K PVJ:PCZHVHS:P39QP_V
M9J]W$RP75_:F.YG"AI9F;IY&)_XB?S*>'R/(Y0YKN+JT4Y1Z^\KV?PW7\L;I
MN3<3R,3'Q<I257"9%DDXJ23BZM&,I0>_O*]FWRWCI[D$XMR;1V(_;)^$E]\+
M--^(]EX3\07%MJ.MV?A0>%)M.M1K*7,T;7%K'J45S-%9P6*V@CN8WO7*F*6
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MP3.2><]\=Z7_ (9*_:5_Z(QX^_\ !;#_ /'Z_GN7 G%\924.#.*Z$$VHT*.
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M^C_ADK]I7_HC'C[_ ,%L/_Q^C_4;C+_HD>+_ /PWXG_Y$7_$)?$C_HW7&_\
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M\&7R3_V7X<O8+K1=68#R[:6\F=KBS&01YB2>9<<Y(^T#@$YK]<'6-9O-1<(
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M^^?_ *]'U3'?]"RI_P" 3_R#^QLW_P"A37_\%_\ VA@;1Z_^@_\ Q5&!Z_\
MH/\ \56__P (YJ__ #Z7/_?/_P!>@^'-6 )-G<D <C;U]N3BCZIC?^A94_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2518361d1_424b5img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2518361d1_424b5img003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $H KP# 2(  A$! Q$!_\0
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M]:I?66IQ;CA]/:-*ZYFE>RC=O0)W=*?LTW4L^5?#T[NVM^]O,^'OA!^WM?\
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M .(KXE.G'15*=KNS<XW:OI?KMWU/J54YH1<[QG;WH\K]UV6ETK/KM?UV+!(
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M%O*/WW_(]+G7:7_@++E%4OM4G_/(?]]-_P#$4?:I/^>0_P"^F_\ B*7M:?\
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MZ5\?5Y9*T91WZR2ZQ?7T9])S+M+_ ,!9=HJG]I?_ )YK_P!]/_\ &Z/M+_\
M/-?^^G_^-UIS1_FC]Z%SKM+_ ,!9<HJG]I?_ )YK_P!]/_\ &Z/M+_\ /-?^
M^G_^-T<T?YH_>@YUVE_X"RY15/[2_P#SS7_OI_\ XW1]I?\ YYCCGAGSQ_P
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M+:DFFDVTTTP7AWE#O;B7BK3_ *K?-_UPJT/GK_A%O^"BG_0^?L\?^$KXK_\
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M\U?4U8?BH]ACD_$2_P#!?O\ 9)4;6\ _%Y'7@HVC^'LKUX8+XB7#=. O&<$
M@Y0_\%^OV1.K^ _C"&.#A='\-E03[GQ 2.!ZGG/2OT*'AEXZ5)2A3\*YU)0:
M4XTN&55<;ZIM4HR=FMGJKV5]4?#O%>$\XP<>.LW:G'VD/^%SB%.4=KZX>ZU:
MT=GUMH?;_P#PB'_!0S_H?OV>_P#PD/%/_P M*/\ A$/^"AG_ $/W[/?_ (2'
MBG_Y:5\/_P##_?\ 9"_Z$3XQ?^";P[_\O:/^'^_[(/\ T(GQB_\ !-X=_P#E
M[6G_ !"[QX_Z--BO_$1J_P#RHCV_A5_T76;_ /A^X@_^9S[@_P"$0_X*&?\
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MV+X;.#W/.NY!_7/-->%_CS?WO"/%I;_\DE5D]/+V*M]Y3J>$R5X\=YQ?2_\
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M]?\ A+>*?_EK7W__ &&G_/5?^_0_^*H_L-/^>J_]^A_\51_K1F/_ $ <,?\
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M#OY2^NS<&GM/EFXNSY)-<K2\,,'?_D=<5_\ B;YSW_[ M7Y:7[]_B+_A%O\
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MX\_\([6__D2E_K-PS_T.,-_XD,O_ ) 7]CYS_P! &??^$V,_^4'&>8_]X?\
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M '\D_P#BZ/,?^\/^_DG_ ,779_\ "MOB-_T('CS_ ,(_7/\ Y$H_X5M\1O\
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M0N)N&79?VSA?_$AE^;A;UUT#^R,Y_P"@#/O_  FQ=O\ TR<=YC_WA_W\D_\
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M%7PQ\/>&+'P%HGC#P9IUSIVL6B:GXL:PAEO8;Q+JYT+7[/4+'5=1C28FZNM
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MO&WA?7$@\*_#;Q&ET+SQS<:YJ,OB>&[L#/,;HZG9?V?JEMJ,$CV^"DN" 7O
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M_P"@O-/NQG_SR%_9V#_Z%V!_\((__,Q0_P"$6\+_ /0"T?\ \$UC_P#&*/\
MA%O"_P#T M'_ /!-8_\ QBK_ -AM/^FO_@0_^-'V&T_Z:_\ @0_^-'US'?\
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ME!)RBL+1M%-V6])[O3XI,H?\(GX9_P"@#H__ ()['_XQ1_PB?AG_ * .C_\
M@GL?_C%:GV&#_GI)_P"!$O\ A1]A@_YZ2?\ @1+_ (5E_:.-_P"@K-?NQ?\
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M71FQN]%;\J0L>R,?PQ53["G]Z3_O[)_C5:ZA2WC#D3.I=5.R9@5!SELMV'<
MY.< 'FMTG)I+5O1+17?S]"HIR:BE=O9:+HWNVELGNUL:>]O^>;?I1O;_ )YM
M^E<YYT *#R[L;I/+_P!<P*LV=K,O4(V,%^B_Q$<4YW@B0O*ERAVY11<%O,*L
MH94(QN* ACQC:/7&9;2DX/XENM[?==?B1"<*BG*$E*,).$I:J',G9VF[1DD]
MY1E*,>LD=#O;_GFWZ4;V_P">;?I6 S0 G,=X2)7BRLA894C:SD']V'!RN_&
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M^J_XT?\ $KO@)_T07#G_ (*S7_YZA_Q&CQ,_Z*[B#_PGA_D?O3_Q$#?M0_\
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M_ 75?_DFOP6V3>GZK_C1LF]/U7_&C_B5WP$_Z(+AS_P5FO\ \]0_XC1XF?\
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M@/#G+,SS+*)UY?7H49YU0KX=4Y5XS2@JE*&-=22YJ=1S3H+EY4U*?-:7W6.
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M-*UWVZK\RQ$G[L(Q+8P,M@L<*O).,9SGH!]*F P !V&/RJNLT87&[G'/3&<
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M+' 484Y/,,UHQ47&C_9SYZTJ3?-[R=-_N;J][1]_E5NW\('_  Z(_P""@O\
MT0#6?_"A\*__ "YI/^'0_P#P4$.?^+ :T,_]3%X6]!Z:UC_/?K7]XF8\9\Z/
M_O\ 1 _J!^M&8Q_RVC/OYL7\@#C\SQU-3+Z=?C?+1Y'P="VMUAIZ^7NS;\]=
M!+Z+G *=UF_%R?\ UZ3_ /<3[?\ #G\'?_#H7_@H%_T0#6O_  H?"O\ \NZ/
M^'0O_!0+_H@&M?\ A0^%?_EW7]XF8_\ GM'_ -_HO\*,Q_\ /:/_ +_1?X4_
M^)Z?'#_H3\'_ /A-5_\ DP_XE=X!_P"AQQ;_ ."%_P#*3^#O_AT+_P % O\
MH@&M?^%#X5_^7='_  Z%_P""@7_1 -:_\*'PK_\ +NO[Q,Q_\]H_^_T7^%&8
M_P#GM'_W^B_PH_XGI\</^A/P?_X35?\ Y,/^)7> O^AQQ;_X(7_RD_@[_P"'
M0O\ P4"_Z(!K7_A0^%?_ )=T?\.A_P#@H(/^: :UQTSXB\*_C_S&C_\ J^IK
M^\3,?_/:/_O]%_A1^ZQ_KXP?:6(X].N,^O3V]Z7_ !/5XWIW>2\'3W5GAJG6
MVOO32TL#^B[P#US?BY[;4;?^X4?P:2_\$B/^"@8)S\ -:.2/^9A\*^G_ &&N
M/;UZU*G_  2'_P""@>W(^ &M=21_Q47A7';'36NF.V/H,&O[P)6A&<3KGC&7
M7 SGCA2.3W'/UP*>IBZ"9<>K2(/PPRC'UQ@CCK5/Z=7C=)6_L/@V/6ZPTT_3
M2HWK?= OHN< K59OQ=?M[';_ ,HZ^FK_ #/X/O\ AT+_ ,% N_P UK_PH?"O
M_P NZ/\ AT+_ ,% O^B :U_X4/A7_P"7=?WB9C_Y[1_]_HO\*,Q_\]H_^_T7
M^%3_ ,3T^-__ $)^#_\ PFJ__)A_Q*[P#_T..+?_  0O_E)_!W_PZ%_X*!?]
M$ UK_P *'PK_ /+NC_AT+_P4"_Z(!K7_ (4/A7_Y=U_>)F/_ )[1_P#?Z+_"
MC,?_ #VC_P"_T7^%/_B>GQP_Z$_!_P#X35?_ ),/^)7> O\ H<<6_P#@A?\
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M%/AJATKM_P#@2_.-CY#_ .%:^+O^@;??]]VO_P ?H_X5KXN_Z!M]_P!]VO\
M\?KZ\W1_W[?_ +Y:C='_ '[?_OEJO_7+,?\ GW3^Z7_R8O\ 5JA_S^?_ ($_
M_D#Y#_X5KXN_Z!M]_P!]VO\ \?H_X5KXN_Z!M]_WW:__ !^OKS='_?M_^^6H
MW1_W[?\ [Y:G_KEF/_/N'W2_^3#_ %:H?\_G_P"!/_Y ^0_^%:^+O^@;??\
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M2,7<9WK\ML0>1Z@\>O7'UH ^"?&W[-'Q[\>6%EJ.J>(O@=8>*K6_6*UC\/\
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MKQE&2[J46O\ THV/(B_NT>1%_=JG)JUE#";B639 JEVD(RJH Q9CCGY0I)4
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M?IZ_H?Z-'FV/_/*#_OF/_P"*H\VQ_P">4'_?,?\ \57^<O\ \-=_M2?]%_\
MB[_X7VM?_)5'_#7?[4G_ $7_ .+O_A?:U_\ )5'_ !3SXW_Z.#PQ_P"&3B;_
M .;0_P")MLK_ .B2SS_P\TO_ )0?Z-'FV/\ SR@_[YC_ /BJ/-L?^>4'_?,?
M_P 57^<O_P -=_M2?]%_^+O_ (7VM?\ R51_PUW^U)_T7_XN_P#A?:U_\E4?
M\4\^-_\ HX/#'_ADXF_^;0_XFVRO_HDL\_\ #S2_^4'^C1YMC_SR@_[YC_\
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M_P#/6/\ -J^+/^$Q\4?]!N['_;7_ .M1_P )CXH_Z#EW_P!_?_L:T_U!Q/\
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M9X(U>7Q7X<T[4];TRW\4OH.MZS\&+[Q?X<T>6;4+YX/MM[X?\6SK9W]Y(]S
MZ;YT:X8+^^G]G3H5*X8(QD8LRAK@!)@D$A  6-6%N0P^9L;G)(-(^ER9380
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M_P"CE=5_\(W3/_CE'_$Z7@#_ -%)C?\ Q%^+?_EX?\2Z>,/_ $3=/_Q+J/\
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M+IFC_P!DW+ZMJ6F,UA8PP&6XE1 0/9O"G[/WP^\$:A:ZEX9TB2RN+/6M5UN
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M *M[_P >LW^Z/_0EJ0=!_NP?^AFH[W_CUF_W1_Z$M2#H/]V#_P!#- $U%%%
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M*7Q5>>!;?QKX>N/&>GS&VO/"T&I6TFMVUR+47HMI;!9#,MPUD?M:P8,IMP9
MF!1"]3G]FG-4X\U1PC*2IQO;FG:+Y8MW5Y65]-6.4X02<Y1BF[)RDE=K5I7>
MKMKZ:GI-%45U*T:'[0)?W)C:;S"K!?)6/S#(>,JNSYAO"GG!P>*@M]9TVZMK
M>\MKJ.XM+J(7-M/"V^.6V;:!<1L, V^'1O,&4"NISAAF8SC*,IQ=XQ^)I-J/
MJ[: YPC:\HI2T5Y)7?9:Z]S5HJ!+B-U#+NP1QE2.V?;MSQ4P((!'0C-*%2G4
M3<)1FD]7%W5_NW*\Q:S)I6%Y&JID*I&2..<YP1U[\=L^A-:=>5^/?BU\//AB
MD&I_$'Q=H?@[3)KL:;!J'B&]@TRUGO&@-P(8IK@JCMY7S84G!(7@FMJ=.I6J
MTJ%&G4K5ZTG"C1I4ZE6K5FHN7)3ITJ=2<Y<J;Y8Q;LFTG:Q%6I3H4JM>M4A2
MH4(.I6K59QITJ5--1<ZDYRC&$4VDVW;4].1V*J3&<XY QUS_ )Z5*I) )!7/
M8]1]:^9A^V/^RZ5!_P"%Z_#,'K_R-&F9/H0/._IU/;/+U_;#_9>90W_"]_A@
M,]0WBO20V<GJ#<9&>,_AZBO0EDF>1NI9)G$7&7*[Y5F>DK7Y7;+FT[=&D>5#
MB'(:C2AG652;CSI+,<%K"ZCS*^(BG&]E=/<^EZ*^:?\ AL']E[_HO/PO_P#"
MKTG_ ./T']L+]E[O\>?A=^/BS2?_ (__ )YJ?[&SK_H39M_X:\S_ /G::+.\
MF?\ S-LLOV_M' __ #8?2U%?-/\ PV'^RY_T7CX6_P#A6:5_\D4?\-A_LN?]
M%X^%O_A6:5_\D4?V-G7_ $)LW_\ #5F?_P [A_VUD_\ T-<L_P##A@?_ )K/
MI:BOFG_AL/\ 9<_Z+Q\+?_"LTK_Y(H_X;#_9<_Z+Q\+?_"LTK_Y(H_L;.O\
MH39O_P"&K,__ )W!_;63_P#0URS_ ,.&!_\ FL^EJ*^:?^&P_P!ES_HO'PM_
M\*S2O_DBC_AL/]ES_HO'PM_\*S2O_DBC^QLZ_P"A-F__ (:LS_\ G<']M9/_
M -#7+/\ PX8'_P":SZ"OYI%V!(RRYSD#/)&<'/'Y9'O5Z!VDC#,I5N 01@\
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M.@_W8/\ T,U'>_\ 'K-_NC_T):D'0?[L'_H9H FHHHH **** "BBB@ HHHH
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M<VT%PD4Z-#/$LT2L(YHF ,4B[@CQD;D8,.QK7B!$: C!"C@U5B@*(J!,!5
M9B6 P.-Q//UY^F,5=7H,\<#BOBXNLY24X484]7%4_B4F[-/HU;9GU$%R4XTV
MW)P6LMTW97_X&NWXK7\[W_!PS"1^SE\+G+LI_P"%M1']T[*Q5=(D(#$,N5&0
M"A)&%R #FOZ(:_GC_P"#A93)^SA\+=O.WXJHIW9 !72)#DEMH.?F'!(..,DD
M5^N>!3BO&'P[<\17H0_UDPO/'#JBZE>/LL2G32KPG!Z>];31ROS*T3\U\8$W
MX<\4<M"6(J++JCITX8F6&FYJ4'>,XM.5DOAU[JS5S^0@R7&6W7<KMN;YP74$
M$@X"[Q@*.#P!QD>E2*7QS/(2>[,Y/&1R0_)QUY/M4.[G'ENN<-@J1@, R@_*
M3RK#M]T]B2* <@Y(]\Y!X[$?F#QUYY/7_?9PHU:M:=&C1PV"3IQ4JU3 82K*
MOR*ZE+!8>5:3<%*7+42AI=OF2O\ Y35JV(Q5'#5\1ATJ%.$J'[W,<9BX0KJ7
M,J?)AJG/3J*$9/WK)133U:)MW_3<_F__ ,71O(P/M#^G63\N&Q_ATJ+"^B_]
M]G_"D/4G(YSUYQSVSQT P3C@TU0H/15\-+K_ ,C*I_\ ,3TUU,8/#IO]UA5I
M;WIYOWZ?O=_N)?-;_GO)^;_TDH\UO^>TGYR?_'*B(.3AQCM\QHP?[X_[Z-/Z
MM2_Y_4/_  X5?_F(U]I0_P"?6#_\'9O_ /)DOFM_SVD_.3_XY1YK?\]I/SD_
M^.5%@_WQ_P!]&C!_OC_OHT?5J7_/ZA_X<*O_ ,Q![2C_ ,^L'_X.S?\ ^3)?
M-;_GM)^<G_QRCS6_Y[2?G)_\<J+!_OC_ +Z-&#_?'_?1H^K4O^?U#_PX5?\
MYB#VE'_GU@__  =F_P#\F3B=EX$SGWS+_P#'!0SLQ!,S#C RSGCD@YW^_OSV
MJ C'4@?\!!_S^7UQD94 D$D9R>3M)QGIC_.#T&<#-0P=.3M"KAY.VRS&=_\
MU#6W6[(G+#R5O9866JT53-V^O15'I^&Q+N_Z;G\W_P#BZ([FXM9H;BWN[F&[
MMY[:YL[NWN)8);.>WN4E1TVN 5DN$MGD?.(DM\/CS%RS#?W6_P#(G_Q/^'X4
MPL84DN$MI;B>,0I!$D4DOFH]U"MQ:*B!F>6ZW1", %B8SM&2<<&;9-EV,RS'
MT,UPV%QN!GA:[K4ZN*]O2IJ-*HUB*D*E"G",:+;DZDI?N^:^MV:826)ABL/+
M+9_5,6J]+EJX669NLZ?M(>TIQ5><H-5(\JDK<S27+J?VI?L-?M#3_M%?LV>
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M8!_Z(%IG_A8>.Q_[L].'_!(']@ #GX Z422<G_A+O'1[^I\4 GUY]:_28QS
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M]UIM_8:E!(WB;QA=,;G3YS<0!XKO6KA7A$A#.A;#=,#&3^CZ)< $&2,\]0I
MQQQ@L.G4^YSQ2D7 .,Q$'NP/XCC(QG.<\\GVKBJ>*7B3BJ<Z%?Q!XO\ 93BU
M5C6SS.:M*<&K3IRIXEQIRYXMQU][?E3=TMX\#\%P<9OAO)8N$E*+I8>@Y1E%
MWC:RO9-;[=SBK7X>^%HHHX?[*3]R@B79=:B(XX(5$5M%&G]H JD-LD40'.=F
MX8Z597P#X7YVZ<JC.2#<:@>O'&=2XZ8_#VKJV6Y;^*#/]U0Q)ZYYQC/.0?\
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M"//-J,.90YY-1CSM74>9VCS-;*]VMD7IFVQ2-W6-S^2GGZ9KS[XA^,K3X?\
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M\\U_();2!XE)& !TY[X'  '8'U)Z'FI=Z@;<D'OU/7KSW[=>G3-?[!Q_9T>
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M\Q1_PLO0O^>%Q^8KP3;#_P \I?T_^+HVP_\ /*7]/_BZ/]4<M_DJ_P#@:_\
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MFFN-JSU6%5GMK5_^4O0%X?X-MI8_$.VCMJUZI2=NF]CY,_LV\_YY)_WYN?\
MXBC^S;S_ )Y)_P!^;G_XBOK38GM_W[C_ ,*-B>@_[]Q_X4?Z[5_^@1_^5?\
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M+@,<1/-&4BEF4F,E<$^B/^V#8Z&_B2+5_#FK^*ETO6?B;;K/X7TFWM#I^A>
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MC^9J#_@K?^T1!$8(]#\%!$4*-VGS[CV)#-J>>3R"#SQZU&/^"N/[1@&%\/\
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M^6E,;_@KE^T;P$T3P42<YSIER>F, '^T\\C/3'3\::^E1X0O_E_FO_@BNO\
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M6I_\\8?^_#__ !5'_"PM3_YXP_\ ?A__ (JOK?\ 6K)?^@G%?^"I_P"1]_\
M\1#X;_Z":W_@M_\ R1[9Y$7]YO\ OND:!"!A^01U(;@YSQD9' SSQ7BG_"PM
M3_YXP_\ ?A__ (J@_$/5.GE08]X'/M@<\'' /KQCN''BK)>9?[3BGKLZ4]7M
M;;KM]PUX@\-3?*\365_^G;O>S=E[SWM;YGLSV^5Y?@D'*D CD=?F)&!GC..<
MC(&*JI%%]JNE\WYWV'!;'8#C&<YR!TZ8!Y'/CLOQ%U<J0D< ;<-I,+8)# X
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M$5%S5TKI.2@^5>[,^'<R_P!_]?\ ZU&9?[_Z_P#UJ^XO^'<W[7/_ $2B\_\
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MK&OHW^.C=O\ B%O&W_AOP/\ D?#&9,$[QQ[_ %]O:DW2?\]!^?\ ]:ON=_\
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MUU04*52$XRKX:HHSDDDTDZ?QJ+>D48^YNVW\Q_B/Y#Z4;F_V?S'_ ,571_\
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MEAG5T*PQIYH.X;AO+*.-W&['0Z3I%EH^G66CZ980:5INFP1VFFV5FFV"UMH
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M94 _I@#TY_&G=WMS-/YM_=>_X#O"I;GDY1W5IWU]>>VU^I)YEKZI_P!]0_\
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M8)RWW>?O8Q@YS2O%;M+MJO\ ,5UY;I/5:-[+U?1;OHF3_:+?_GO#_P!_4_\
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MY=)OK&94+ZO!]K%TD$C;'C*C!48^I;3]MOX9W7BC7["Y<6?A32/#'AK5]/\
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MPSNM,\?Z!XR\37^D:=I>E>(?"]UIEQ<RZY(([ NMRL<R12L0$!B*.QX;@9^
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M? M]XB/Q TFSUN.VN-:@T.P\/6ESH%EJDGVS5FT_4;B74+?[6T:PV\-G:23
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M>_YUM_JK@.WY?_(A_P 0\R;^5_A_D?./_"'ZK_SZ/_W]/_Q-'_"'ZK_SZ/\
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M4%6Q@9)&5SVX&><BN]EBV(Y"G/ !YP3O7ICDY&?4^GK4;-BYE8!B-L:@#/&
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< *EQ<03P@E2>>QZ=<G@'^Z?<<X.#DZU%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
